

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau





# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:
C12N 7/00, C12P 21/06
C12Q 1/66

(11) International Publication Number: WO 93/16172
(43) International Publication Date: 19 August 1993 (19.08.93)

(21) International Application Number:

PCT

PCT/US93/00913

(22) International Filing Date:

2 February 1993 (02.02.93)

(30) Priority data:

07/833,431

7 February 1992 (07.02.92) US

(71) Applicants: ALBERT EINSTEIN COLLEGE OF MEDI-CINE OF YESHIVA UNIVERSITY [US/US]; Yeshiva University, 1300 Morris Park Avenue, Bronx, NY 10461 (US). UNIVERSITY OF PITTSBURGH [US/US]; Cathedral of Learning, Pittsburg, PA 15260 (US).

(72) Inventors: JACOBS, William, R., Jr.; 163 Fordham Street, City Island, NY 10464 (US). BLOOM, Barry, R.; 61 Summit Drive, Hastings-on-Hudson, NY 10706 (US). HATFULL, Graham, F.; 6 Forbes Terrace, Pittsburgh, PA 15217 (US). (74) Agent: GEORGE, Kenneth, P.; Amster, Rothstein & Ebenstein, 90 Park Avenue, New York, NY 10016 (US).

(81) Designated States: AU, BB, BG, BR, CA, FI, HU, JP, KR, LK, MG, MW, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published

With international search report.

(54) Title: MYCOBACTERIAL SPECIES-SPECIFIC REPORTER MYCOBACTERIOPHAGES

#### (57) Abstract

This invention relates to mycobacterial species-specific reporter mycobacteriophages (reporter mycobacteriophages), methods of producing such reporter mycobacteriophages and the use of such reporter mycobacteriophages for the rapid diagnosis f mycobacterial infection and the assessment of drug susceptibilities of mycobacterial strains in clinical samples. In particular, this invention is directed to the production and use of luciferase reporter mycobacteriophages to diagnose tuberculosis. The mycobacterial species-specific reporter mycobacteriophages comprise mycobacterial species-specific mycobacteriophages which contain reporter genes and transcriptional promoters therein. When the reporter mycobacteriophages are incubated with clinical samples which may contain the mycobacteria of interest, the gene product of the reporter genes will be expressed if the sample contains the mycobacteria of interest, thereby diagnosing mycobacterial infection.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT AU BB BE BF BG BJ BR CA CF CG CH CI CM CS CZ DE DK ES	Austria Australia Barhados Belgium Burkina Faso Bulgarla Benin Brazil Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon Cyzchoslovakia Cyzeli Republic Germany Denmark Spain Finland	FR GA GB GN GR HU IE IT JP KP  KR LI LK I.U MC MG MG MIL	France Gabon United Kingdom Guinea Greece Hungary Ireland Italy Japan Democratic People's Republic of Korea Republic of Korea Rezakistan Liechtenstein Sri Lanka Laxembourg Monaco Madagascar Mall Mongolia	MR MW NL NO NZ PL PT RO RU SD SE SK SN SU TG TG UA US VN	Mauritania Malawi Netherlands Norway New Zealand Poland Portugal Romania Ressian Federation Sudan Sweden Slovak Republic Senegal Soviet Union Chad Togo Ukraine United States of America Viet Nam
--	---	--	---	--	---

15

Ç.

# MYCOBACTERIAL SPECIES-SPECIFIC REPORTER MYCOBACTERIOPHAGES

### STATEMENT OF GOVERNMENT INTEREST

This invention was made with government support under NIH Grant Number AI26170.

#### FIELD OF THE INVENTION

This invention relates to mycobacterial species-specific reporter mycobacteriophages (reporter of making such mycobacteriophages), methods such reportermycobacteriophages, and the use reporter mycobacteriophages, for example, to rapidly diagnose mycobacterial infection and to assess drug · susceptibilities of mycobacterial strains in clinical Specifically, this invention relates to the samples. mycobacterial species-specific luciferase use o£ reporter mycobacteriophages to diagnose tuberculosis and to assess the drug susceptibilities of the various tuberculosis Mycobacterium of strains -(M. tuberculosis).

To produce the mycobacterial species-specific reporter mycobacteriophages of the invention, transcriptional promoters and reporter genes are introduced into the genomes of mycobacterial

10

These reporter species-specific mycobacteriophages. luciferase the genes for the may which and provide the DNA B-galactosidase gene, The reporter encodes production of a gene product. mycobacteriophages may be used by incubating same with samples which may contain the specific mycobacteria of If the mycobacteria of interest is present, interest. reporter mycobacteriophages introduce the recombinant nucleic acids which encode expression of the gene product into the mycobacteria of interest, and the mycobacteria then express the gene product. The expressed reporter gene product may be detected by a suitable assay, for example, through the detection of photons or the conversion of an easily assayable chemical reaction. The presence of such gene product 15 indicates that the sample contains the mycobacteria of interest, and hence the mycobacterial species-specific reporter mycobacteriophages may be used to detect and thereby diagnose the specific mycobacterial In addition, since signals may not be infection. 20

generated by cells which are not metabolically active the presence of antibiotics, the mycobacteria species-specific reporter mycobacteriophages of this invention may be used to assess the drug

susceptibilities of various strains of mycobacteria. 25 If antibiotic drugs are added to the sample containing the reporter mycobacteriophages and the gene product

is detected, the mycobacteria is metabolically active and hence resistant to the antibiotic drug.

#### BACKGROUND OF THE INVENTION

5

10

15

20

25

In 1990, there was a 10% increase in the incidence of tuberculosis in the United States. addition, there has been an increase in the appearance clinical isolates of tuberculosis resistant to antibiotics used to treat the disease. This problem is exacerbated by the length of time that is currently needed both to diagnose tuberculosis, and to determine the drug susceptibilities of various strains of M. tuberculosis. As a result, patients with M. tuberculosis may remain infectious for long periods of time without being treated, or may be treated with a drug to which the bacterial strain is resistant. Therefore, a need has arisen in the field for a method of diagnosis of M. tuberculosis (and other mycobacterial infections) which is rapid, sensitive and specific, which method is also capable of assessing the drug susceptibilities of the various strains of M. tuberculosis and other mycobacterial strains. It is critical that a mycobacterial strain be assessed for drug resistance rapidly because a patient infected with a strain of M. tuberculosis or another mycobacteria must be treated immediately with the particular antibiotic drug(s) to which the strain not resistant, and not with antibiotic drug(s) to

20

25

which the strain is resistant, or the patient may die.

Currently, the most rapid test available for the diagnosis of M. tuberculosis is the staining of sputum samples for acid-fast bacilli, which is a tedious procedure, and which procedure has diagnosis methods Alternative sensitivity. require cultivation of the bacilli for approximately two to six weeks followed by classification of the cultured organism. Typical diagnostic tools include analysis of mycolic acids tests, biochemical All of these tests are time-consuming. serotyping. More recently, the use of oligonucleotide probes and Polymerase Chain Reaction have been suggested for the identification of M. tuberculosis species. Although these methods may be useful approaches, their uses in a clinical setting have not yet been determined. Further, these methods do not distinguish between live and dead organisms, and are therefore of limited use in the determination of drug sensitivities of clinical isolates.

In addition, Mycobacterium avium (M. avium) is a mycobacteria which is often found in immunosuppressed patients. This mycobacteria is typically disseminated throughout the bodies of immunosuppressed patients, such as AIDS patients, and causes M. avium infection. Because this mycobacteria often causes death in immunosuppressed patients, it is

6.

10

15

20

25

necessary to be able to diagnose and assess the drug susceptibilities of the various strains of M. avium.

It is therefore an object of this invention to construct broad mycobacterial host range and

5 mycobacterial species-specific reporter mycobacteriophages.

It is another object of this invention to provide mycobacterial species-specific reporter mycobacteriophages which may be used to rapidly diagnose mycobacterial infections.

It is still another object of this invention to provide mycobacterial species-specific reporter mycobacteriophages which may be used to rapidly assess the drug susceptibilities of different strains of mycobacteria in clinical samples.

It is yet another object of this invention to provide mycobacterial species-specific reporter mycobacteriophages wherein the reporter genes are luciferase genes, which mycobacterial species-specific reporter mycobacteriophages may be used to rapidly diagnose mycobacterial infections and to rapidly assess the drug susceptibilities of various strains of mycobacteria.

It is a further object of this invention to provide mycobacterial species-specific luciferase gene reporter mycobacteriophages which may be used to rapidly diagnos tuberculosis and assess the drug

susceptibilities of the various strains of M. tuberculosis.

## SUMMARY OF THE INVENTION

This invention relates to broad host range and mycobacterial species-specific reporter 5 (reporter . mycobacteriophages), mycobacteriophages, methods of producing such reporter mycobacteriophages, and the use of such reporter mycobacteriophages to rapidly diagnose mycobacterial infection, such as M. tuberculosis, and to distinguish which strains of 10 the mycobacteria are drug-resistant. To produce these genes and mycobacteriophages, reporter reporter transcriptional promoters are introduced into the genomes of mycobacterial species-specific mycobacteriophages. The promoter and reporter 15 gene-containing mycobacteriophages (reporter incubated with then mycobacteriophages) are clinical sample which may contain the mycobacteria of interest, such as M. tuberculosis. The reporter mycobacteriophages are specific for the mycobacteria 20 which is sought to be detected. The introduce mycobacteriophages efficiently recombinant nucleic acids which encode the expression of the reporter gene's gene product into the mycobacteria of interest, and the mycobacteria then express the gene product. A substrate or other means

That years is a fireblack and when all a solutions

10

capable of allowing for the detection of the gene product is then added to the sample. If the gene product or the signal generated by the gene product is detected, the presence of the infectious mycobacteria

is known, thereby diagnosing the disease. To assess drug susceptibility of mycobacteria, drugs such as antibiotics ma; be added to a sample containing the reporter mycobacteriophages of this invention. If the mycobacteria are susceptible to a drug after exposure to the drug, the mycobacteria will be killed.

However, drug-resistant mycobacteria will continue to be metabolically active in the presence of the drug, and will continue to express the detectable gene product of the reporter genes.

- invention are the Firefly luciferase <u>lux</u> gene (FF<u>lux</u>), the luciferase <u>lux</u> genes of <u>Vibrio fischeri</u>, the luciferase <u>lux</u> genes of <u>Vibrio fischeri</u>, the luciferase <u>lux</u> genes of <u>Xenorhabdus luminescens</u> and the <u>E. coli</u> ß-galactosidase gene (<u>lac</u>Z). The
- preferred promoters of the present invention are hsp60 and L5 gene 62 promoter, and the preferred mycobacteriophages are L5, TM4 and D56A. These reporter mycobacteriophages are preferably used for the rapid diagnosis of tuberculosis and M. avium
- 25 infection, and the accurate assessment of drug susc ptibilities of the various strains of M. tuberculosis and M. avium.

15

20

25

## BRIEF DESCRIPTION OF THE DRAWINGS

The above brief description, as well as further objects and features of the present invention, will be more fully understood by reference to the following detailed description of the presently preferred, albeit illustrative, embodiment of the present invention when taken in conjunction with the

FIGURE 1 represents the genome organization of mycobacteriophage L5;

accompanying drawings wherein:

FIGURE 2 represents a luciferase shuttle plasmid pYUB180 wherein reporter gene FFlux is fused to the BCG hsp60 promoter;

FIGURE 3 represents the amount of luciferase activity of <u>M. smegmatis</u> which contains the pYUB180 shuttle plasmid and the FF<u>lux</u> gene;

FIGURE 4 represents the effect of various antibiotic drugs on the metabolic activity of control mycobacteria and drug resistant mycobacteria in the

presence of reporter mycobacteriophages which contain luciferase reporter genes;

FIGURE 5 represents shuttle plasmid phAE39 wherein the reported gene is FFlux, the promoter is hsp60, the phage is TM4 and the cosmid is pYUB216.

FIGURE 6 represents luciferase activity of

M. smegmatis cells infected with shuttle phasmids

phAE39; and

20

25

FIGURE 7 represents a flow chart for cloning different promoters into TM4:: <u>lux</u> shuttle phasmid phAE39.

#### DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to mycobacterial

5 species-specific reporter mycobacteriophages,
 (reporter mycobacteriophages), methods of producing
 such reporter mycobacteriophages and the use of such
 reporter mycobacteriophages for the rapid diagnosis of
 mycobacterial infections and the accurate assessment

10 of mycobacterial drug susceptibilities.

In order to produce such reporter mycobacteriophages, species-specific mycobacterial mycobacteriophage genomes are modified by introducing therein transcriptional promoters and reporter genes whose gene product can be sensitively detected. reporter mycobacteriophages may then be incubated with clinical samples containing suspected of the mycobacteria of interest, either directly of after culture, and the samples tested for the presence of reporter gene product, thereby diagnosing mycobacterial infection.

The method of this invention allows for rapid diagnosis because only the amount of time necessary for the reporter mycobacteriophages to infect their host cells and the amount of time n c ssary for the host cells to synthesize the reporter gene product are

requir d to allow for diagnosis. Typically, the amount of time required for the reporter mycobacteriophages to infect their host cells and for the host cells to synthesize the reporter gene product is between ten minutes and sixteen hours.

The assessment of drug susceptibilities with the reporter mycobacteriophages of this invention is accurate because the reporter mycobacteriophages only allow for the detection of metabolically active mycobacterial organisms, the presence of which metabolic activity indicates that a drug has not killed the mycobacteria and that the mycobacteria is resistant to the drug.

To enhance diagnosis specificity, a series of similar reporter mycobacteriophages, each of which having well-defined but different specificities for mycobacterial species, is selected.

Mycobacteriophage L5, a temperate virus with a broad host-range among mycobacteria, is the most thoroughly characterized of the mycobacteriophages. L5 particles are morphologically similar to the family of phages that includes phage g and contain a linear dsDNA genome with cohesive ends. The inventors have determined the DNA sequence of the entire gene as well as several gene functions. The DNA sequence of the L5 mycobacteriophage is as follows:

あって、いま「岩質質などであ

20

25

1	GGTCGGTTAT	GCGGCCGAGC	CATCCTGTAC	GGGTTTCCAA	GTCGATCAGA	GGTAGGGGCC
61	GGCACAGAAA	CCACTCACAT	CAGGGCTGTG	CGCCTCCAGG	GCGCGTGAAC	TCCCACACCC
121	CGGTGTAGTT	ACATCCCGGA	ATTGTCTCAG	CCCCTCTCAG	CCCCCTTCTC	ATABACACEC
181	ATCTACGCCA	CTCCTGACGG	GTCCCTCTCX	ACCATA CTCA	CCTTCCCTTC	WINNACAGIG
241	CTARCACCC	CTCTCTATAG	BCCCCCCCCC	ACCCCCCCCC	CCLICCCIAC	TAATGAGGGG
301	CIANONUCCC	CICICIAIAG	AGCGCCGCAC	AGGCGGCGCG	ATAAGAGCGC	CACCAGGCGC
361	TCATCTAAAG	ACCGGCCTTG	AAGGGCCGGT	CATAGAGATC	TATTCGATCC	GGCAACCGCC
421	GGATCTCAAG	GCCGCGCCAG	TGCGCGGCCC	TATAGAGGGG	TGACTCAACT	GTGCATGGCA
481	CTCGCTCGAG	TGCCCACTGG	AGCACTCAAC	CGGGGAAGTT	CGACGTTCTC	AACCTGCGAA
	TGACGTTTGA	ATCGTCATCC	GCGTACGAAA	TCCCCGATCT	GCGGCCGACC	GACTTCGTGC
541	CGGCCTATCT	CGCGGCCTGG	AATATGCCGC	GTCACCGCGA	TTACGCCGCC	AAGAACGGCG
601	GCGCGCTGCA	CTTCTTCCTT	GACGATTACC	GGTTTGAGAC	CGCGTGGTCG	TCCCCCGAGC
661	GCCTTCTCGA	CCGCGTAAAG	CAGGTCGGCG	CTGCACTCAC	GCCGGATTTC	AGCCTCTGGA
721	CGAACATGCC	GAAGGCGGCG	CAGCTATGGA	ACGTCTACCG	CTCCCGCTGG	TGTGGCGCGT
781	ATTGGCAGTC	GGAAGGAATC	GAGGTGATTC	CGACGGCGTG	TTGGGCGACT	CCCGACACGT
841	TCGATTTCTG	TTTCGACGGG	ATCCCGATGG	GATCGACCGT	CGCAATTTCT	TCGATGGGCA
901	TTCGCTCTTC	AAAAGTCGAC	CAGGAGCTTT	TCCGGTACGG	ACTACGCGAA	CTCATCGATC
961	GCACTCAACC	GCAACTGCTT	TTGGCATATG	GCCAGCTTCG	GCATTGCGAC	GACATGGATT
1021	TACCAGAGGT	CCGCGAATAC	CCGACCTACT	GGGACAGACG	ACGAAAGTGG	GTAACTGCCG
1081	ATGGGAGGCC	GGGGAAGTAA	AGGCGGCCCC	GGTCCCGGAA	CCGGAGCACG	CAACCGCAGA
1141	GGCGCTGGAG	CCCCGGATC	GGGCGGCGTA	GGCGGCGTCG	GAGGCGGGG	TGGAGCTGCA
1201	GGGAGCAGCG	GAGGCGGCAA	GGGAACGGCA	GCGCCGGTAC	CGGAGGCGTC	ACCGGTGGCG
1261	GCGGAAGTGG	AGCCGGCGGC	GGTGGCAGCA	GCCCCAACAC	CCCGGTGCCC	CCCICCGIGC
1321	TGGAGAAGAA	GCGCGGCGAA	TACAACCAGA	TCGCCATCGA	CCCCCAGAAA	CAGCACGCGC
1381		GAAGCGCGAG				
1441		GGACCCGGAT				
1501		CTCCGAGGAG				
1561		ACTCAAGTCG				
1621		CCTCCTCGAG				
1681		GTTCAACGGC				
1741		GGACTCGGTC				
1801						
1861		CGTATTCCCC.				
1921		GGGGCTGGTC				
1981		CAAGAAGTAC				
2041		CGAGGACATC				
2101		GGACGAACTT				
		ATCGAGGGGT				
2221	GAACGGCCAC					
2281		TACGAGGGTC				
		AGCGAGGTCG				
2341	GCCGGCTCAG					
2401		CTGCCAACTG				
2461	ACCGATGTCG	ACCACATCAA	GCGCGGGAAC	GACCACAGCC	GGTCCAATCT	GCAGGCAGCC
2021	TGCCATGTCT	GTCACGGCAA	GAAATCAGCC	GCCGAGGGCG	TAGCCCGACG	GCGGGAACTT
<b>5281</b>	AGAGCCCGGA	GGAAGCGACC	ACCCGAACGC	CATCCTGGGC	GTCGATAAGC	GGGCCAGGTG
2641	CCCGCTCCAC	CCAGGAGGTG	AACAGTGGGC	ACGCGAGGCC	CAATCGGAAA	ACGAGATGAA
. 2701	GAGCGGGTTC	GTCGGAACAC	CCCGGACAGT	CCAACCGACA	CGATCCAGAT	GCCCGGTCTG
2761	GTGACGATCC	CCGAGATGGG	CGATCTAAGC	CACGACCGCC	GCACGCACCA	GCTCGTCAAG
2021		• •			•	
7077	GACATGTACG	AGTCGATCAA	GCAGTCGGCA	GCCGTGAAGT	ACTACGAGCC	GACCGACTGG
- 700T	CAGATGGCCC	GACTCGCCCT	TTD C D C TTT	AACCAGGAAC	TCATCGCAGC	CCECENTAR
. 234T	GGCAAGCCCG	TGGGCGCGAT	GAAGCTCACT	GCCATCAACC	AGATGCTCTC	CGCGCTGCTG
. 2001	"CTGACCGAAG	GTGACCGACG	CCCCCCCCA	CTCGAAGTCG	AACGAGCACC	CCCTCLCCC
SAGT	· ACAGGCGGGA	AGGTCGTTGA	CGTGACCGAC	GTGCTCAAGC	AGCGCCTCGC	CAAGGCGAGC
3121	GGCGGGAGCT	GATGGTCCCC	CGAGGGGTTT	CTAGAGCCGC	TGCCGCTACC	AGCCGCTCCC
3181	CCTCGGGGTA	GACATCGAAA	GGAACCACAT	GGCCGACCTC	GGCAACCCAC	TCGACCTCGA
					• .	

2047	CAMCOMOTICO	CTGGTCACAG	CCCCCCACTT	CCCCTGGACC	ATCGATTACC	CGTGGGGTCC
3361	TOTCACCOGG	AACGACCGGAG	CCCACAATCC	GCAGGGGCTG	GCAGGCGACA	TCCAAGACGC
3421	CATCGACTAC	AACGACGIGI	COCCANACCO	TGTCGTGCAT	CCGGTCTCGC	TGTTCCCTGC
3481	TCTGGACGCA	GCCGTCGGAG	CCGGAAACGC	CAAGCCGCTC	ACCGAGCAGT	TGGTCAACAC
3541	GTGGACACTG	AACTTCAACC	TCAACGCCAG		CAACTACTTG	GGGTCGACGT
3601	GATCAACAAG	GCCGCGAACG	ACTTCTTCGA			GGGICGACGI
3661	GGAGATGACG	GTCACCGACA	CCCTGAACTT	CAAGCTCAAG		
3721	CGATGAGGTC	GGTGTCGTCA	CGTTCGCGGT		AGCCAGGCAG	TCATCAACTT
3791	CTTCAACTCC	GTCGCCGAAC	TCACCGGAGC		GTCAACGTCG	ACTTCTACTG
3841	GAACCGGACG	TATGACATCG	AGTTCACCGG		CTGCAGCCGA	TTCCGGCTAC
	<b>BLOSOCOS</b> C	*******	TOCCOCCTAC	CAGCAAGGCC	GILLICAGILA	CGGTGGTCGA
3961	CCCAGGAAAG	AAGAGGCTGA	CCATCTGGCC	GTTCACGGTC	AACGGTGAAA	CCGCAACCAT
4021	CARCETCAR	TCCGAAGAGG	CCGACAAGAT	CCCCAACCGC	IGCCGCIGGC	VOIIOGIION
4021	CANGGICGAG	GGCGAGGCAG	CCGCCGCCGA	TGCAAAGCAG	CTCGGCCGCG	TTTACCGACA
4001	CATGCCGACC	CA CCCCA CCC	ATCAGAGATG	GTGGGCCAGA	CGGCCTTCGG	GCCGTCCCCT
4141	GCCGAGGTAA	CACCGCACCC	VICVOVOVIO	TOTTLATOGG	GTGGTTGAAG	GTTCGAGTCC
4201	GACGTGTAGC	TCAATGGCAG	AGCGCCCGAC	CHCHCCCCCC		CCGCAGGCGG
4261	TTCCATGTCA	GCGAGGGCTG	AACCGGACCC	GIGICCGGIG		GAGCAGCGGT
4321	. TTCCCCAGAG	CGTGGGGAGC	CCCTGCCCTG	TACACGTAGC		
4383	- CTCCAAAGCC	GCCGGTTCCA	GGTTCGACTC	CTGGCGTGTA		TAATCGGTAA
444]	GCTAGCGGAG	TGTTCGCCTT	TCGGGCCTGG	GGTCTTTTTC		TWYTCOATUR
450]	LGACACCCGGC	TCTGGACCGG	GCAATTGAGG	TTCGAGTCCT		CCAACTTGAC
4561	LATCCACCCGA	AAGGAACAAC	ATGACCTTCA	CAGTCACCCG		CAGTGGGTCC
4623	LACGACATEGO	CCGCGCTCGC	GACGGTCTCC	CCTACGCGTA	CGGCGGGGGG	TTCACCAACA
448	3 CCCC3 CCC3	* CTCCACTCAC	тестствесс	TGGTGCTGCA	CACCGGGGCI	TGGTATGGAG
474	CTCCCACCG	CTGGGTCGGA	AACCGTTACG	GCTCAACCGA	ATCGTTCCGG	CTCGACCACA
480	BCNTCCTCT	CGACCTAGGG	TTCAAGCGGA	TGCCCCGAGG	こしじじじししればしい	GCC110ccou
106	1	, <i>c</i>	CCCCTCCNGC	LACGGAGGCGG	しほじじじょしょれし	TCGCACACCG
402	1			LCTGGCCCGGT	CAAGATGTCC	GACCGAGGCG
100	- CLICCACGI	GTCCCACGGC		CCGTAGGCGT	COMMUTITION	GAGGGGGG
504	1 TCGACTGGG	A GICCCACOOC	TTTCCATCACT	TTTGGTACCT	GGACGCAGTC	CICOMONCO
504	- GGGCATGGA	A CGACCCTCTC A TGACGAATTC	CCTCACCCA	TTCTAGGGAA	GATGATCCGC	GAGATCCACG
210	1 AAGGAGACG	r TGACGAATTO T CAATCAGACO	COCTOCCACCAC	CCCATCTGGC	GACCCCTGGT	
522	+ CGTGCCTGT	r caatcagace r acaccagaa	GCGICGACCA	TTCACCCCAT	CCTCCACCCC	
.528	TCTGGCAGC	T ACACCAGAA( C TCGCGCAGG(	AICCACICG	, 1.GACGGCA.	AATCGTGTTC	GCCGCGAAGG
534	1 AGCGGCGCG	C TCGCGCAGG	GATCTCGGT	ACCIDENCES	CCAGAGCATO	CTCGCCGACA
540	T CCITGGGCG	T GAAGCGCGA	GAGGTGACC	A MGCGGGICIA	ACABAGAGG	
546	<b>⊥</b> TCGAGCGGG	A CAACCCCGA	A GTACTTCAG	GATACATCGC	, recececco.	GGCCTATGAG TGCTGGGCAT
552	1 CCCCAAGAT	C CGACAGACC	A TCTACCTGC	r CGGCACCGCC	, GCCCCGGCA	
558	1 CGTCCTGAT	C TGGGGCGGG	C TCGACGCTG	A GTCGGCGGC	CACCICGGI	ACATCATTGC
564	l GGGCGTCGT	G TCGATACTA	G TCTCCGGTG	C GCCGGCCG1/	A GCGGCAGGC	A CCGTACGCAG
570	11	A ALCCOCLOS	P. TCTCCXCCX	C CCGGTGGA		1 700000100
576	1 corecmeen	c ccccccacc	C BCBCTGCCG	A GGCTGAAGT	C GCGAAGGIC	A AGCAGGGGG
E07			<b>- CTCTCCCC</b>	a comocacicu	- LIGGLLACO	- Unurcavers.
588	1 CCTCCCTG	C GACACCGTC	T GGCGTCCAT	g agcaagccc'	r ggctgttca	C CGTCCACGGC
	and the second s				and the second s	
594	1 ACAGGCCA	GC CCGACCCG	CT CGGGCCTGG	T CIGCCIGCC	G ATACCGCAC	G GGACGTACTT
600	) L GACATOTA	CC GGTGGCAG	C CATCGGCA	C TACCCGGCA	G CGGCGTTCC	C GATGTGGCCG
606	il TOGGTOGA	AA AGGGTGTC	C TGAGCTGAT	'C CTGCAGATC	G AGCTGAAGC	T GGACGCAGAT
612	21 CCGTACGC	GG ACTTCGCG	IT GGCCGGCT	LC TCGCAGGGA	G CCATCGTGG	T GGGCCAGGTG
618	31 CTCAAGCA	CC ACATCATC	AA CCCGAGAGG	T CGACTGCAC	C GGTTCCTGC	A CCGGCTCAGG
62	AL AAGGTCAT	CT TCTGGGGT	AA TCCGATGC	G CAGAAGGGC	T TTGCCCACA	C CGACGAGTGG
	Ol ATTCACCA	GG TCGCTGCC	C GGACACGA	G GGCATCCTC	G AGGACCGAC	T GGAGAACCTC
63	61 GAGCAGTA	CG GCTTTGAG	T CCCCCACT	C GCGCACGAC	G GCGACATGT	A CGCCTCCATC
	21 AACCACA	CG YCEAGGAC	COCCONCIA	ים פרטיתנטאני ים פררזייינפר	C GAATCGTGA	T GAGCGCTAGG
64	AAGGAGGA	CO CACCOLLO	CA GIACGAGG.	TO GCCATIGGC	A TEGAGETTE	G ACAGCGTCCG
65	- CGATTCAT	CO GAGGTAAG	on Ciccolor	TO BUCCHOUSE	בה בככת כביול	T CTTCGCCAAG
22	ATCTGGGA	GG GAATCGCG	NI GUCCAGAG	TO WICHICONC	TO TOTAL	ביד רכב פידיררים
60	TCGACCCA	AG .GCCCGAGC	IG GCCGCATT	re TACAACCEC	* "ICCCGGCGG	GT CGAGTTCCTA
00	CGACGAAT	CT GAGAAAGG	AG GCGGGGTG	AG CCTCAACA	CACCACCC	G AGCTTGCCCC
6/	4+ GTCTCCCC	CT CACATCAT	CG GCCCGTCC	rg gcagaagac	GICGATGG	TOTATORTOA DE
67	B1 GCCTGAGA	AG ACCCTCGG	CT GGGGAGTC	CT GAAGTGGC1	C TCCGAGTAC	CG TGAATACCCC
	TGGCGGGC	AT GACGATCO	GA ACCGTCTG	GC GACGTTGA?	C GCGCTCTC	G AGGCAGGTCT:

6841 TCTCGA: AAC GAGAACATGT TCATCCCCAC CGACGAGCAG GTACGCCTGG TCCTCTGGTG 6901 GTACGCAGTA GATGACCAGG GCCAGTACAT CTACCGCGAG GGCGTGATCC GCCGGCTCAA 6961 GGGCTGGGGC AAGGATCCGT TCACCGCCGC GCTCTGCTTG GCGGAACTCT GTGGCCCCGT 

	10441	ACCTCTGGAA	CCAGTCCGGT	CACGACCTTG	AGAAGTTCCG	CGAGGAGACC	AGAGAGGACT
:	10577	TCGAGAAGTG	CCACCCACCC	でここと このこでで	TECTECTOOC	CCTCTTCGAT	CTCCACAACT
	10501	GGCCCGGAAG	CACGCAGG	IGCOVCIOIC	A COLA A COUNTY	CATCGAAGCC	ACCCACCAAC
	10261	GGCCCGGAAG	AGACGCTGCC	CTACGGGCGC	AGCAACITIG	CARCARCC	AGCGACGAAG
	10621	CTGACGACCT	CATTGCGTCA	GGCAAGGCCC	GCTCCAAGAA	CAAGAACACG	GAGACGCTCA
	10681	ACGCGCTCCG	ACGCCGCCTA	GCACGCGGCG	AAATCACCAT	GTCCAACTAC	GCCCTCGCTG
	10741	CGTAGTCCCT	CGAACCCCAG	GTGGGTTCTC	TCAACATGCC	CAGGAGGCGA	AAACACATGT
	10801	CCGACAACCC	CACTCCCGAG	AGCACCCCAG	AGGCCGAGAC	CCCGGAGGTC	GAGAAGCCGA
	10861	TGGAACCGCA	GGGCAAGGTC	TTCGATGAAG	CGTACGTTCA	GTCGCTTCGC	CAGGAGGCTG
	10001	CAGCCGCTCG	CCTCCCCSSC	PROCECCO	TACAAGCGCC	AGAGGCTCGA	GTGAAGGCCG
	10371	CAGCCGCTCG	GGIGGCGAAG	AAGGACGCCG	INGANGCOCC	ACAR CECCAC	A A COA CEECC
	10981	AGTACGAGGC	CAAGCTCGCT	GAGCGCGACA	CCGCTTACAC	CGAACIGCAG	AACCAGIIGG
	11041	GACAGGCGTG	GATTGAGCTG	GAGAAGGTCT.	ACCTCTCTCT	CGACGCCAAG	GTGCCCAACG
	11101	ACAAGGTTCG	GGCGTTTGTC	GAGATCCTCG	AAGGCAACGA	CAGGGACAGC	ATCGCTGAGT
	11161	CAGTGAAGTC	CCGTCTGGAG	CTGGTCGGCG	GATTCGGCAA	CAAGACCCCG	AGTCCTGCGT
	11221	TCGACCCGTC	TCAGGGTCGC	GGCGGTAAGC	CGCCGATCCC	GCTGAACGGT	GACCCGATCC
	11281	TOCACCOAT	CARCCCCCC	CTCCCCATCA	AGAAGTAACC	CACCCAACAG	ATCTCAAGGA
	11201	ICGAGGCCAI	CAAGGCCGCI	GICGGGAICA	CACCA CCCCC	ででしてでではない	TGAACGACCC
	11341	GAGATAAACA	ATGGCAGTCA	ACCCTGACCG	.CACCACGCCG	1.0010000	I GANCOACCC
	11401	CAAGGTCGCG	CAGACCGGCG	ACTCGATGTT	CGAGGGCTAC	CTCGAGCCCG	AGCAGGCCCA
	11461	GGACTACTTC	GCCGAAGCGG	AGAAGATCTC	CATCGTCCAG	CAGTTCGCCC	AGAAGATCCC
	11521	GATGGGCACG	ACCGGCCAGA	AGATCCCGCA	CTGGACCGGC	GACGTGAGTG	CGTCGTGGAT
	11581	CGGTGAAGGC	GACATGAAGC	CCATCACCAA	GGGCAACATG	ACCTCGCAGA	CCATCGCCCC
	11641	CCACAAGATC	CCCACCATCT	TOGTOGCCTC	GGCGGAAACC	GTCCGTGCGA	ACCCGGCCAA
	11701	CTACCTGGGC	ACCATCCCCA	CCNACCTCC	CACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCGATGCCGT	TCGACAACGC
	11701	CTACCTGGGC	ACCAIGCGGA	CCMAGGICGC	CACCOCCITC	CCCCCCCCC	CONCOCCE
	11/61	CGCGATCAAC	GGCACCGACA	GCCCGTTCCC	GACCTTCCTA	GCGCAGACCA	CCAAGGAGGI
	11821	CTCGCTGGTG	GACCCGGACG	GCACCGGCTC	CAACGCCGAC	CTCACCGTCT	ACGACGCGGT
	11881	CGCCGTCAAC	GCCCTGTCGC	TGTTGGTCAA	TGCCGGCAAG	AAGTGGACCC	ACACTCTGCT
	11941	GGACGACATC	ACCGAGCCGA	TCCTCAACGG	CGCGAAGGAC	AAGAGCGGTC	GCCCGCTGTT
	12001	CATCGAGTCG	ACCTACACCG	AGGAGAACAG	CCCGTTCCGC	CTCGGTCGGA	TTGTGGCCCG
	12061	TCCGACCATC	CTGAGCGACC	ACGTCGCCTC	GGGCACGGTC	GTCGGCTACC	AGGGTGACTT
	12121	CCCCCACCTC	GTCTGGGGCC	AGGTCGGCGG	CCTCTCCTTC	GACGTGACGG	ATCAGGCGAC
	12181	OCOCCAGCIC	CCCACCCCC	ACCUTCCA A	CTTCCTCTC	CTGTGGCAGC	ACAACCTCGT
	12241	TCTGMACCIG	CECALCICCO	AGGCTCCGAA	CIICOICICO	CACAACCACC	CCTTCCTCAA
		CGCAGTCCGA	GTCGAGGCCG	AGTACGCCTT	CCACIGCAAC	GACAAGGACG	COLLCOICAA
	12301	GCTCACGAAC	GTGGACGCCA	CCGAAGCCTG	ATCCAGGCTT	GACATCCACC	GGGAGGGGG
. '	12361		GCCCTCTCCT	'GATGTGGAGC	AGGAAGGACC	ACATGCGAAT	CCAGTCCACC .
	12421	CTCAACGGCG	GTTTCGCCGA	GGTTTCCGAG	GAGTTCGCCA	AGCAGTTGAT	CGCCACTGGC
	12481	GGCTGGAAGG	TGCCCCGGAA	ACCGCGCAAC	ACCAAGACCA	AGACCGCTCC	TGAGGAGCCC
	12541	AAGAACGAGG	AGTAACCCGT	GGCCTACGCG	ACCGCCGAAG	ACGTTGTGAC	GTTGTGGGCC
	12601	AAGGAGCCTG	AGCCCGAAGT	GATGGCGCTG	ATCGAGCGCC	GGCTCCAGCA	GATCGAGCGC
	12661	ATCATCAACC	CCCCCATCC	CGACCTGGAC	GTGAAAGCCG	CTGCGTCGGC	GACGTTCCGG
•	12721	VIOVICAVOC	TCCACATCC	ACCTCATCCT		TCGTGCGTAA	CCCGGAGGGC
	12781	GCCGWICIGN	I ICOMONICO	, woctowiect	プラウング ひょうしょう	AGGCCGACCT	GTCGCAAGGC
	12841	TACCICICGG	AGACCGACGG	, IGCGIACACC	TAICAGCICG	TO A DOCCORCO	GARGCGCATG
	12901		TCCTCGATGA	GGAGTGGGAG	AICCICGGGG	TCAACTCCCA	CACCCCCCCC
	12961		TCCCGAACG	GGTGATGCCG	ACGTGAGCGC	GAGCGACCGA	CACCOCOCCC
		· CGATTGTCTA	\ TCCGCCTGG(	: ACTCAGGCGG	TTACGCCGGA	TCGGGTCAAC	GCGTTTGACT
	13021	GCGATCACGA	AGCTGATCC1	CCGGTGTGCC	GGTGCGTCCA	CGACTGGCGC	ATCGAGTGGG
	13081	GANACGTCA	L GAAGGCCACO	CCCAGATCAC	GGTCGGCGGI	: GCTCTGATGA	GCCTCCTCGA
	1314	CACCGGTGCC	CGGTACCAG	A CCTGCATCGT	' CTACCCCGAA	. GAGATGGTCA	TCGACTCCGA
	1320	TECCARCAR	CGGACCAGG	CGTCGAATAC	CGGCATCCCG	GCCATCGCAC	GGTTCCAGGT
	13261	A G C C A A C C A C	TOTOTACO	r cecenceace	TOUTGAGUAG	GACAACGAGG	GGTTCGAGAC
	1332	CCACAACCA	TOLUGIACO.	r commences	, CTCCTTCAC	AAGGAGCACG	GCATCCTCGG
	1338	CGAGAAGGI	- INCCOUNTED	- GOTTICCCC	CICOTICUC	, ARGURGAGO , CTCTTCCGAG	ACCCCACCCT
	1344		CAGATCGAG	r GGCGAGACCA	. GCGGTGGGCG	CTCTTCGGAG	ACCCCACCCC
	1350	CTACGACTC	A TCCCCTGCG'	r TGGCGCGGG1	CGACTACAC	ATCAAGAGGT	ACTUATOUCC
			3 CGAACGCGA	A CAAGGICGCO	GCCCGGTACG	TCGAGACGAG	GGACGCCGTC
	1356	L CCAGACGAG	" GGAACAAGG	r caccegrega	N GCCAAAGCC	A ATCTGGCGCG	GCAGAACTUG
٠,	1362	ACCACCGC	A TCACCGACG	A GGGCTACTTO	: CCGGCCACC	A TCACCGAGCA	AGACGGCGAT
•	1368	* GTCGACTTC	C ACACGATCC	T CAACGCGCCC	: AACGCGTTG(	3 CGCTTGAGTI	CGGCCACGCG
	1374		יים	G CACCGACAC	AAACCACCG	G AGGCCACTTA	CATCCTCACC
٠.	1380	1 000000000	* ************************************	C CCTCTCXXX	GCAGGTCAC	TGGCGCGAAT	GCCTCGCGTC
			A ICOUCUCA	C CAICICNIN	- GAVGGTCVC	TGGAGGGAG1	GACGGTCACG
`	1392	1 CAGGCAGTA	G CGGCCCCGA	1 CUILLIGUIL	1 GMCLCCCM	A WCYFCCCC	CCGCATAGGC
	1398	MI MILIPLYLY I	CAGACGTGG	A CITICOGAGA	- FICULGATO	2	CCGCATAGGC AATGACCGCC
		- 1.6.6.6.11.6.6.	A ACCCCAACG	C ACCGACGCT	• CACACGCTG		/ WWT GWC CAC

14041	TACACCAGAG	ACGGTCTCAT	CGAGACTGAG	GAGCTGTACG	AGACCGCGCT	AGAGGTTCTC
14101		TGGAGAACGG				
14161						
		CCACTCAGTT				
14221		GCGTCCGCAG				
14281		CGACGCAGTG				
14341	GCACCGCTGC	TCCTACGCCG	GCCTTGCTCA	AGACCATCGA	CCTCAGCAAG	CCCGAGACCT
14401		TACCGGTTGG				
14461		AGGCGGCGAG				
14521		CGAGGATCCC				
14581						
		TCTGTACTAC				
14641		GACCAACGAG				
14701		CGCCCACAAG				
14761	ATGACCTGGC	TGCGCTGCCC	GTCCGGTTCA	CCTACCTGGA	CCACGAAGAC	GAGCTGCCGT
14821	TCTCCTGGAT	CAACGAAGAC	CTCTTCAACG	TGCCCGAGGT	TCCCGAGGGC	TGATCCCAAC
14881	TTGACAGCCA	CCCGGCTGTC	TACCCCGGAG	GGGGAGGTTT	CCTTGGCGGG	CCTGGCCTCC
14941		GCCACTCACA				
15001	CACCATCGAC	GCATTCCGCG	AAGAGGTCAA	GARGARGTAC	GCTCCGGTCC	TCATCGGCCT
15061						
15121	GTCCGACGAT	GTGACCGTCG	AGCTGAAGCC	GCTGCTGAAG	CTGGGCCAGA	AGGCCCGCGA
15181	AGCGGTGGTC	GAGGTGTTCA	AGGAGTTCGC	GGACATCCCC	GACCTCGAAG	AGGACGACGA
15241	CGACGAGTTG	GTCGATGAGT	ACTCGCTCCA	GGTCTGCGAC	ATCATCGCCA	AGGCGTTCCG
	GCTGATCGCC	ACGAAGCCCA	AGAAGCTGAT	CGCCGCCTTG	GACGAGGAGC	CGGATCCCCG
15301	TATCCGCGCA	GAGCTGTATG	CAGCGGTACT	CAACACCTGG	AAGCGAGAGA	CCCAACTCCC
15361	GGAAGCCGCG	CCCTCGCCGA	GCTGATCGAC	AAGTTCGGCG	CCCCCATCCT	CCCX CX CCCC
15421	CTCCAGTACT	ACCGGGTAGA	COTOCCOR	CACALCOCCO	ACCACCATCC	COCHONCEIG.
15481	AGATTCCTTC	TGTCCCTGGT	CCIOCOCOAC	CIGIICCGCG	ACCAGGATCC	GCTTTCGCCG
15541	COTTOTTC	TOTCCCTOGI	GCTCTGCCTT	CCCAAAGACG	GCGCGTTCTA	CGCAGAACGT
15601	CACCCCARCC	AGCAGTACCG	GGGCTGGACC	GAGGACCGCT	ACGCGCTCGC	GGACATCTAC
15661	GACGCCATCC	AGGCGGGCAA	CCACATCCTG	CTGCTGGCGA	ATCGTGATCC	GAAGAAGCCA
15721	AAGCCCAAGG	CACCCAAGTC	ATACCCGCGT	CCCGACGACC	TAGAGAAGAC	CACACCGAAG
15781	CCGGGTTCGT	TCGCCGCAAT	GGTCGTGCGA	GCGAAGAAGG	CGGCTCGAGA	GAGAAGGGAA
15841	AGGGAGGAGG	AGAGTGCCGA	ATAGTGCTGG	CGTAGAAGTC	GCCCGGATCT	CGGTCAAGGT
	CAGCCCGAAC	ACCAAGGAGT	TCCGCCGGGA	ACTCAAGACC	GAACTCGAGA	AGATCGAGCG ·
15901	GGAGCTTAAG	GGCGATGTCG	AGATCAACGG	TCATCTCGAT	GCGGCCCAGG	CCAAGGCCGA
15961	CTTCAAGCGC	ATGATGATGC	AGCTCAAGAC	CGAAGCTGCC	AAGGGCGTTC	ACGTCCCGGT
16021	CGACGTAACC	GTCGACAAGA	AGAGCAAGAA	GGGAGGTCTC	CTCGGAGGTC	TCCTCGGCGG
16081	CAGCCGGGG	CTCGGAGATC	TAGGCGATGA	CGCCGAGAAG	GCGTCGTCTC	AAGTACAACA
16141	CCTTGGCAAG	TCGTTCCTGG	GCCTCACACG	AGCCGCCTGG	ATAGGCGTAG	GCATCGTCGC
16201	CGTAGCAGCT	CCGCTGGTCG	GCATCGTGGC	CGGTCTGCTG	GCCGGTCTGC	CCTCCCTCCT
16261	GTCTGCGTTC	GGAGCCGGCG	CTGGCGTAGT	CCCCCTCCCC	ATGGACGGCA	TCAACCCACC
16321	CCCCCCCACC	CTGGCCCCGA	CCCTCCACACA	CCTCBACCCC	VI GOVEGGEV	CCACCOMMCCA
16381	GCAGGGACTC	ACCCCGGIGT	DOCTOON OUT	GG1CMMGGCC	OCCUPANT OCCUPANT	CONCOLLCON
16441	CCTCCACAA	WCCCCGG-G1	ICCAGCAGCI	CGGCCCGAIG	CIGALLUCGA	TCACCCCCAA
16501	CCIGCAGAAC	GTGGCCTCGG	GCCTCGTGAA	CATGGCCGGG	TCGATCACCG	ACGTGATCAC
16561	CCAGGCTCCT	GGTCTGCAGC	AGATCCAGAA	CATCCTCACC	AAGACCGGAG	AGTTCTTCAC
16621	GGGCCTCGGC	CCTGTGCTCG	CTACCGGCAC	GCAGGCGTTC	CTGACGCTGT	CCAACGCCGG
16681	CGCGAACTCG	TTCGGCACGC	TCCTGGCTCC	CCTGCAGGAG	TTCACCAACG	GCTTCAACGA
	CATGGTCAAC	CGAGTCACGT	CCAACGGCGT	GTTCGAGGGT	GCCATGCAAG	GGCTTTCGCA
16741	GACGCTGGGC	AGCGTCCTCA	ACCTGTTCAA	CCGGCTCATG	GAGTCCGGTC	TGCAGGCGAT
16801	GGGACAGCTC	GGCGGTCCGC	TGTCGACGTT	CATCAACGGG	TTCGGAGATC	TCTTCGTCTC
16861	GCTGATGCCG	GCGCTGACTT	CGGTCTCTGG	TCTGATCGGC	AACGTCCTCG	GGACGCTGGG
16921	CACACAGCTC	GCTCCCATCG	TCACGGGGGGT	CACGCCGGCC	TTCCAGACGC	TGGCGAGCAC
16981	GCTCGGCACG	ATGCTCACCG	GAGCCCTCCA	ACCTCTCCCT	CCGATCCTGA.	CTCAGGTCGC
17041	TACCTTCATC	GGCACGACGC	TGBBCBCGC	CCTCCTGGGT	CTCCAGCCGA	TECTECCETC
17101	CCTCATCCAC	AGCTTCCAGC	1 CR MCMCCCC	CCLOCKOOCT	CICCAGCEGA	CCCCCCACAT
17161	CCCCCCCCCCC	AGCIICCAGC	MCCCCCC CCC	CGIACIGGIG	WCCWGICIOG	CCCCGCACAT
17221		GCGACGGCCC	TCGGCCAGGT	. CGCAGGCGCG	GIGCIGCAGC	TUGUTUUGAU
17281	GATCATCTCG	ACGTTGGTTC	LGGCGTTCGT	TCAGTTGGTC	CCAAAGGTCG	CTGAGCTAGT
17341		GTCAACCTGG				
17401		CTGGTCAGCG				
		GGCGCGCTGG				
17461		GTCAGCAGCT				
17521						
T\28T.	TAAGGATCTC	GTCCAGGGCC	TGATCAACGG	CATCGGCGGG	ATGGTCAGCG	TGCAGGCCGG _ CAUCUUTCAA
	Page 1	Salitaria de mario de Sala		figure and the second of		

17641	CAAGGCCAAG	GAGCTGGCGT	CCAGCGTGGC	TGGTGCAGTG	AAGGGCTTCC	TGGGCATCGA
17701	GTCCCCGTCG	AAGTTGTTCA	CCGAGTACGG	CCAGTTCACC	GCCGAGGGAT	TCGGCAACGG
17761	CATGGAGGCA	GGGTTCAAGC	CCGTCATCGA	ACGGGCCAAG	GATCTCGCGG	CTGAGCTGTC
17821	CAGGGCGATG	GAGTCGGGCA	CCGACCCCTC	CGGGATTCTC	GCTGGGCTGG	ATCAGAATGA
17881	GCTGAAGCAG	ATGCTGGCGG	CTCTCGAAGA	GGAGCGCAAG	CGACTCAAGG	TCGAGAAGAA
17941	CGGTATCCCC	AAGGGAGACA	AGGCAGGCCG	AGAGGCGCTG	CAGAACCAGC	TCGACCAGAT
18001				GCGTGACCGC		
18061				GAAGGCAGCC		
18121						
18181				GTTCCTTTCG		
18241				CATCCAGTAC		
18301				GGAGTCGAAG		
18361				CATTGATCAC		
18421				CGACCGGTGA		
18481				CCGTCAAGGT		
				GAGCCCTGAA		
18541				CGCGCTCCTG		
18601				GCAAGCTCTA		
18661				AGTCCCCCAC		
18721				TGTCGTGCAT		CCGTTCTGGT
18781				CCAAGACCGA		GACCCGTCGT
18841	TCTGGACGCC	GCCGTGGCCG	TGGGAGGAAC	TGCCCAAGGA	GACGCTGCGG	ATCAAGGTCG
18901	GCCGCGAGCA	GGGTGGGCTA	AACCCCACCG	ACCAGTACAT	CTTCCCGAAG	TGGACCGTTC
18961	CCGGCTCCAC	CGAGAAGGTG	CCGAACTTCC	CCTGGCCGTT	CCCCCGAAC	GTCCCGATCC
19021	CGTGGGAGAC	AGCACCGTTC	ACTCAGTTCG	TCATCCCGGA	CTACTCGTTC	GAGGATGAGG
19081	AGTTCCGCAA	CCGCCGGCTC	<b>AAGACGCCGG</b>	GGTTGATCTA	CGGCGAGAAC	TGCGTCATCG
19141	ACACCGACCG	GCGCGAGGAG	CAGATCGCTT	CCGAGTCGGG	CTCCCCGGTG	TGGGCTCGGA
19201	TGAACGGTGT	CCGGTTCCGC	AACTCGATCC	CGCCCTACAC	CGAAGAGGCT	GAGTTCGTCA
19261				TAGTTACCCT		AGGCCGTGGT
19321	CGCGCTGCTG	GGGGCTAGAG	TGAGTGGTCT	GACGAGCGTT	CGTGAGGCCG	AAGATCTCTG
19381	GCAGAAGATC	CAATTGCGGC	GCTGCAAGCG	CGAGCAGGAA	CGGCTCAAGC	ATCCCGACGT
19441	AGAGCTGCGC	GATGGCGACT	TCCGCCTGCG	CGGCCTGGTC	GCTGGCGAGC	GGGTGCTCGA
19501	GTGGGAGTTC	ATCGAGAACG	AGACTGGCAC	CTGCACCTTG	CAGCTCTCAC	TGAGCCATTA
19561	CCTGGCGAAG	TGGGTGATGG	ACCACCGGGG	TCGAGCAAAG	CGCAACGTCA	TCATCAACAT
19621	CGAGAAGCAA	GGCGCTCGAT	GGACCGGGAT	GATGGACCAC	TACCGGGTCA	TCAAGACCGA
19681	CGCAGGGGAC	GCCTACATCG	AGATCGTGTT	TTTGCACGAC	TTCGAGCAGA	CCAAGCATAT
19741	CCGGGTATGG	TGCAACCCGT	TCCTACGCCC	CGAGCTGCAG	TTCCCCAAGG	TGTGGATCAT
19801	CTTCGGGCCG	GCCAAGTGGT	GTTTGCTGGT	GACACTGTTC	GTCAACCTGC	TCAGGCTCGA
19861	GACGAGCTTG	TGGACGCTGC	CTGATGACCC	CACGGACATC	AACGAGTGGA	TGGGTCCGAG
19921	CTTCAACCCA	GCAAATTGGC	GGAACATCGT	CAAGCCGTTC	CCGTTCCTGG	CCGACAACTC
19981	ACCGGTCACG	ATGGTGTTCA	GCCGGTTCGG	GACGTTCTAC	GACACCGCCA	AGAAGATCCT
20041	CGAAGACCAT	CAGCTCACGC	TGACGTGTCG	TCGGTACATC	AAGGACCGCG	ACCCGCATCC
20101	GTTCGAAGAT	CTCAAGGGGC	TCTGGGGAAT	TGATCCTGTC	GAAGACCTGC	TGCAGAAGAT
20161	CCCGCTCCGG	GACGGCTGCG	TGGTCTGGGA	CATCGAGGAC	AACTCAGGTT	GGGGCACTCA
20221	CACCCCCTTC	GCCGCTTCGT	GGCTGACCGG	GTTCGTCCGA	GGGATGGTCC	AACTGGCCGG
20281	CCACCCCTTC	CTCCAGGGC	TCGATGTGTT	CACCGGGGAC		
20341	CTACTCCCC	TGGTTCATGG	CCACCAGCCC	GATAGCACCC	CACGTCGTGT	TCGAAGAAGG
20401	ACCECTEACE	CCCATCAACT	CCTCCCACTT	CTCGTACTAC	GAGGCCACCG	
20461	CCTGCTGCC	CCACACACCC	CACCTCCCAT	CAACGAGGGC	ATCTCGGCCC	TGGTGAACAT
20521	CCTGGCTGGT	CTCCTCBCCT		CAGCCAGCTC	CCCCCCTCC	GCGCGGTCGG
. 20581	TCCTCCCAN	CIGCIGACCI	COLICATOR	TCTGCTCGAT	CCCCTCTTCC	AGCCTCTGTA
20641			TOTALCES SOL	TCCGACTCTG	CGTGCGATGG	GCATCTCGCT
20701	CICCONIGIO	. TICOGCOCO	. TOWNOOMAGI	CGGACTCTG	になったかけったかった	ACTTCCACAA
20761		, GOGCICGAGG	ACATCGTCAC	GCTGTCAGCG	THE TECHNICAL STREET	TCTTCGUGGG
20821	CATGGCCGAC	, GOOGGOATGA	AGGCGTTCAC	CACCCTCAAG	TICOCAGCCA	CCCCTCCCTA
20881	. GAILLAGAN	ACGAGGGCTC	JAACGACCCA	CACCCICAAG	GYALGEGEGEGE	CCGCICCGIA
20941		CURARGUCCI	ACGGGCACT	CTGGATCGGA	MUCCCOSSCC MATCCCCSTCC	- TCAACCTCGGI
21001		CCGGTCGAGC	ACCAGTTGTT	CGTGGAGCGC	ATCCGCAAGG	TOWNSTACES
21061		GACGGCATGA	AGCCGTTGG/	GATCGAGATC	. GGIINCCGCG	CCACACCCCC
21121		CACATCCTC	AAGAGATCA	GCGCGTCAAC	A A CA COCCACA	CANTIOCOUR P.C.
		ACCGAAAGG(	ACGCCGCAT(	ATTCCCTCAC	AAGAGTUTCA	CANTICUGANC
21181	CACCCCCCAC	AGCACGTCAT	GTGGGCGCTA	CGCAATCTCC	CGATGATTGC	TGGCGTCGGG

		_				
21241	GCGATCACGC	ATCCGGGTTA	CCTGGCGGAT	TGGTCAGAGC	ACTTGTGGAA	GTGCGGCTTT
21301	CGGCACGTCG	ACTGGCTCCG	GGAGCTGGCT	GATGAGGACG	GCAACATCCA	CGTCAGTCAG
21361	CTTCCTGACC	AGGAGATCAA	GTTTCAGCAG	CCCTTCCGGG	GCCAGCGAAG	CGACTACAAC
21/21	AACGCAGCTC	CATCCCTCCC	CARAGACGAT	CCTGACCCAG	AGCCCGTGCG	TATTCCAGAC
21421	ATTCGCAAGC	MCN CNCNCCO	CONCARCACA	CCGATGATCG	CCCACTACCA	ACGAGACGGT
21401	TGGATCAAGG	1CACAGACCA		AMACCCCACC	TOUTOUR CTG	ACCCCCCTTCA
21541	TGGATCAAGG	ATGGATCCCC	CGGCCCAGCG	ATAGCCGAGG	ICG1GGVGIG	ACCCCGIICA
21601	ACCCAGACTC	CATAGGCGAC	TACGTGACAC	TGCTCGGCGT	TGCGTTCCTG	ACCITCICGG
21661	TTCCCGCATG	GTTCACCGGA	CGAGCACGCA	AGCACAGCAG	TGACATCGGC	GAAATCAAGG
21721	AACAGGTATG	TAACACCCAC	GACACGAACC	TGCGCGATGA	CCTCGACAGC	GTCAAGGCAG
21781	ACATCAGCGA	CTTGAAAGAG	ATTGTGTTGC	AAGGGTTCCA	CCAGGTGAAC	GAGTCGATCA
21841	ACCTCGAGCG	CCGTGAGCGG	ATCGAAGGAG	ACCGCCGAAA	GGAGGTTGCG	TGACCTACCC
21901	CACCAACCCA	CTAGAGGCCA	TCGGCGCTGA	CGGCGCATTC	GAGATCGGTG	GGGGCGACTG
21961	GAGCTTCGGC	CAGGACTACA	CCGAACAGGC	CATCCGGGCT	CTGTTCACGA	TGCCAGCGGT
22021	CACGATGGAG	AACCCTCTCG	CCTCCTCGA	AGAGCACCTG	CTGAAGCTGC	CTCTGGAGGC
22081	GCTGCAGGGC	TTCBBBCBCB	TEATCCCGGA	CTGGGTCGAA	GGAGCATTCG	ACACGGTCAC
22141	CGGCGCTGTG	TICHARONCA	TONICCCOON	CCAAGACGGC	CCGCTGTTCC	TGAAGTTCGC
22201	CGAGTTCCAG	CAGGGGGTCA	TOVACOCOCI	GAACAACCCG	GCCGAGGTCA	TCGGCGAGAT
22201	CCCCCAGACG	CICITCCIGC	AGCGICIGCI	CCCCCTCAAC	ACCGTCAACA	ACACCATCCA:
52201	CCCCCAGACG	TTGATCGACG	GCCTACAGGA	COCOCIONAC	ACCGIONNON	ACCOCATOCA
22321	GACCATCGTG	GACATGCTCC	TGCAGGCGCT	GGGCATCACC	A COCCAR CCCT	AGCIGATEGA
22381	CCGGATCTTC	GACCTGAGCG	ATGAGATGGA	GTGGCTGCAG	ACCGCAGCCT	CGAATGCAGC
22441	TACCGGCATC	CAGGACACCT	GGAACAAGTT	CTGGGGAGCC	CTCACCGGGC	GCGTCCCAGA
22501	CCAGGACCAG	ACCGTCGCTG	AGCCCGCCGA	GCGTATCGGC	GAGCTGGCCG	GCACCACGTC
22561	TGCTAACTCG	TCTGCCATCG	CGGAGCTGCA	GCGTCGACTG	GACAACCAGC	AGAACGCTGG
22621	CGGCGTGGCC	GGCGGTGACG	ACTTCGAGCG	ACTGAACATA	TCCGGTTGGG	ACATCAGGTA
22681	TTCCAACGGA	TCCAGCGGCC	GAGGGTACTA	CCGTGCCGAC	GGCCACCAAC	TGGTCTGGAT
2274]	CCACCAACCC	AACCAGCAGA	ACACCGCGAC	GTTCGTCCGC	ACCAACCCCG	CAGACGAGAA
22801	GACAGCCACC	CACTACCAGA	AGATGACGTT	GGTCGTCGGG	ACTATCTCCG	GTGAGGTACA
22861	GACCGTGTTC	CCCCCCCAGG	GAGGTTCGCA	CACCCGGCTA	TGGGTCCGCG	TCAACGACAA
2292	CGCTCCGACC	CMCCCCAMCA	CCGACGCGCGT	CTTCCTAGAG	ATCGGCGGCG	TATCGAAGGC
2298	CCAGATCGGC	GICGGCVICY	ACCCCA ATCA	CACCUTCCTC	GGATCTATGG	TCGACTGCAC
2230.	L CTGGGGTGCT	TACCUCCUCCA	MCGGCAAIGA	CCCCCCCACG	GCCAACGGTG	CTGAGAAGTT
2304.	CTGGGGTGCT	GGATCGATCT	TUCCTUTGAL	COCCOGCACO	Grancock	TOTOTOTOTO
2310	1 CGAGGTCTCG	AAGAACGGCC	CCGTGCTGGC	CACATGGTCG		CCNACCTCGG
2316	GATGGGTGCG	AACTACCGCC	GCTGGGGCTG	GGAAGGCCAG	GCICGIAACC	CENTCCICGG
2322	CCAGGGCACT	CCGAACTCGG	TCACCCGAGT	GACGATCACC	GACAACGATC	CTACCGGCGC
2328	1 AGGCGGTGGA	GCTGTCAACG	TCGGAGGAGA	TGTCGTAGGT	GTACTCCCCA	TAGAGAACGG
2334	1 AGGCACCGGA	GCTTCGACAG	CTTCGGCAGC	CCGTACCGCT	CTCGGAATCG	ATGACCTGGT
2340	l carrata	<b>・ ヤクククス ククマス ク</b>	TTCGTGGATC	CGTCGAAGGA	CTCCCGTTGA	TACCGAAGAT
2346	l creceraces	<b>ልሮ</b> ልፎልልሮሮቸሮ	<b>AGTACACGGC</b>	TCTCGCCACC	AAGGATCAGT	CCACGCTATA
2352	1 CPTCAGGACC	COTTABTGAC	TGGTATCTCG	TTGGGTGTCA	ACGACATCCG	CAACCILICG
2358	1 א תיא תיתיתית או (2	こっこうりょうひょう	СВВСЕТЕТС	AAGGTCAGTC	TAGGCACAGA	WANGGICIGG
2364	1 conceenings	CCCCCCCCCCC	<b>・                                    </b>	GCCACGGTCG	GCACGTACAC	CTACAACATC
2370	l ceceneces	· · · · · · · · · · · · · · · · · · ·	CGACGTCATC	CTCCTCGGAG	GAGGCGGCGG	GGGTWWGGC
2376	1 ATGGCCCTGG	COUNCITOUS	CCCCACACCT	GGAGACGCCG	GAAGCTGGGC	TATCGTCACT
2382	1 CTCGAACGCG	CIGACGGCIG	CCCCTTCTC	ACCAAGACGA	TCACCGGGCT	CGTCGGAGCT
2302	1 GGAGGCGCAG	GGGTACACAT	CCCGIIGICG	TC1CCCAAGA	CCGGAGGCCC	TGGAGGAAAC
2300	+ GGAGGCGCAG	CGGGAGCTGG	CICIGIALIC		CCGCCGCGTCC	CGGAGGCTCT
2334	1 ACCACGGCGT	CCGCTGTCGG	ATGGTCAGGT	TIGACCOCAA	NTCCCACCTA	CAACGACCAG
2400	1 GTGATCGACA	L TCCTCAGCGI	CGCCGGAAAG	TCGCCTGGAG	ATCOUNCEIN	TOTEGEGG
2406	1 CTCTACATAG	GCGGCGCACA	ACAGAACTCA	GCTGGCGGG	ACGGCAATGC	cccciacca
2412	GCGGGGCTG	GTGCCCAGG1	CTCCGCACAG	AGCGGCGGTG	CIGGCGCICG	CGGCCAGGCG
2418	31 macamaanna	~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	A CRABACCCCC	· ←₩₩₩₽₽₽€₿	CTCAGTGTCC	TTGGGAGGGG
2426	ll acommonac	7	, CTCTTCCCCC	CCTTGGACA	CGCCTCAGCG	MIMOCEICGI
. 2430	ll accordence	~ 1010000170	*	· TOCOCOLTCC	AGGAGTCGTG	TGACCGAGAC
2431	1 666668	~ ~~~~~~~~~~	* <i>C</i> TCCCACCTC	: cercaceccc	GAACGTAGCG	CCGMCMGCGC
2442	21	C CAMCCCCACAC	r TOCGGCCGAC	' CGATCTTGG(	: GTAGCCACGC	TICAGCGAC.
244	TOJIOUNUU	C CC/CWWCC2	P TOCOGCCOV	י ררוופרפורפי	GGTCACCAGG	AATGCCTCGG
215	TUGTGAACG	C GONCITCON	- WACCAGIIA	, TCTGCGTCG	GATCATCTCC	GCGACGTGAG
245	- GGCCCTTGT	T CATCTTCGT/	- COGICCIIC	, 1010000000000000000000000000000000000	GTTGCCAACG	ACGATETTET
240	y+ GCGGAACCG	I CACAGGACG	TTCGACCGG/	- COULCITOR	* CCACYAGCCC	ACGATETTGT TOTAL
- 246	h :			- 12/2 M 12/ 1-1/ M	I CHILAIDEL	. TC07cone
247	7   mamaammaa	A CACS 1 CATA	へ、カマクカととすぐでん	" CGNACCGGA	3 GLILGILLM	- GCCVGGV11.
247	<sup>81</sup> ATGCCGCGA	T CCGGTAGTG	C TCGAAGATC	CAGCGGCGA	C GATGTCCAGG	TCCTCAGGCG

24841 TCAGCGCCTC TACGTCGCGC TCATCGGCTG CCTTCTGCTC GATCCGGCAC GGGTTCTCTG
24901 CGATCAGCTT GTCCTCGACC GCTGTGTTCA TCACCGCCCG GAGGACGTTG TAGGCATGCC 24961 GGCGGGCAGT CGGGTGCTTC CTACCCATCC CGGCCCACCA CGCACGCACC AGAGCTGGCG 25021 TCATCTCTGT GACCGCCACT TCACCTAGCA CCGGGTAGAT GCGGCGCTCC GCGTGCCCGC 25081 TGTACAGATC CCTGGTGCCG TCTGCGAGGT CGCGCTCCAC GAGCCACTTC CGGGTGTACT 25181 TGTACAGATC CUTGGTGCCG TCTGCGAGGT CGCGCTCCAC GAGCCACTTC CGGGTGTACT 25141 CCTCCAGCGT GATGGCGCTG GCGGCTGCCT TCTTCGCCCG GTCCTGTGGA GGGGTCCAGG 25201 TCTCCATCTC GATGAGCCGC TTCTCGCCCG CGAGCCAGGC TTCGGCGGTC ATCTTGTTGT CGTAGGTCTG CAAGGCCTAGA TACCTCACAC CGTCCTGCGG GTTGACGTAT GAGGCTTGGA 25321 TCCTCCCGCT GCGGTGAGTC CCCATCCGCG ACGTGCCAAC TAGGTCTCCT 25381 CTCGTCGTGA ACAAGGCTAC CGGGTTGCAA CTCCTGTGCA ACTCTCAGGC TTCAACGCGC CGAGAGGGGG TAAAAACCTA TTCTACGACC TTCAACGCGC CGAGAGGGGG TAAAAACCTA TCTTACACCTG CGAGAGGGGG TAAAAACCTA TCTTTACACCTG CCAACTTCTT CCAACTTACT TACGCGGGTT 25501 TCTTGACCGG CCATATGTG GTCGGCAGAC ACCCATTCTT CCAAACTAGC TACGCGGGTT 25561 CGATTCCCGT GGGGGGTCC GCTGGTCAGA GGGTGTTTTC GCCCTCTGGC CATTTTTCTT 25621 TCCAGGGGGTC TGGAACTCTT GTGCGACTCT TCTGACCTGG GCATACGCGG TTGCAACGCA 25681 TCCCTGATCT GGGTACTTTC GATGCTGACA AACGAATAGA GCCCCCCGCC TGCGCGAACA 25741 GACGAGGGGC ATTCACACCA GATTGGAGCT GGTGCAGTGA AGAGAATAGA CCGGGACAAG 25801 GTTGCACCGG GAGTTGCAGC GGTCGGAACC CTCGCCGTCG GCGGGCTGGC GTTCGCCCTG 25861 TCGTTCACGG CTCTCAGCGA GCTGGCTGCG GCCAACGGGG TGGCCCAAGC AGAGATGGTG 25921 CCCTTGGTGG TCGACGGCCT GACGCTCGTC GCCACGGTCG CCACAGTGGC CCTCAAGCAG
25981 AACAGTTGGT ACGCGTGGTC GCTGCTGATC CTGTCCACCG TCGTATCGGT GGCCGGCAAC 26041 GTGGCACACG CCTACCCCCA CGCCATCATC GCGATGGTGA TCGCTGCGAT CCCTCCGCTC 26101 TGGCTACTGG CGTCGACCCA CCTAACCGTG ATGCTGGCGA AGCAGCACTC GGAGCACGCC 26161 GAAGTACCTG TCTCGCGGCC AGAACCCGCG CCTCGGGGCC TGGAGCCCGC TGCCGCTTGA 26221 CTGCGCCCGA CCGGGACAGA AATACATAGA GAACCTATGG ATGTAGGAGG CACAAAAAA 26521 TIGTTGGGGC GGATACTGAT TGGTCATCCC GACAGCCTAC TTGCCGATGG GTCGCATCAG 26581 CTCCTCGACC GACTCGCGCT CCACGCGGAT CAGCCGGGGA CCGAGCCGAA CGGCCTTGAG
26641 CCGGCCGTCG GCGATGTAGT TGCGGACGGT CTTGGTGCTG ACACCGAGGT AGTCAGCGGT 26701 CTCCTGGATG GATCATCGCCATC CGCGGTCCTC CGTGCTTCAT CGCTTGTCCC CGTGCTTCAT CGCTTGTCTC CGTTGTTGAG TTCCTCTGGA CACCAGACC CGATCCTTGC CGCTCTGGAG CTTGTTGAGG TTCCTCTGGC CGCTCTGGAG CTTGTTGAGCTT CACCAGACC TCGAGCTGGT TCCCCTGGGT GATGACACCG TCTTATCCC CGCTGGAGGATTTT CTTGACCTTG TTGGCGATCT CGCCTGCAGA CCCATCGTCA CGCTTACACC CCCTTGCACC CGCGGTTAGATC CCCATCGCC CGCGGTTAGATC CCCATCGCC CGCGGTTAGATC CCCATCGCC CGCGGTTAGATC CCTGTTGTCCC 27001 CGTAGGAGAG ACCCTCGATG CTGTCGCAGT CGCCTGCACC GGGGTAGATC GCTGTGTCGC 27061 TCGCGGGCGAT CTGGTAGATG TCGACGTGCA TCAGATCATC ACCGGGAACA ACTGGCCACC 27121 GGGCATCTGG ATGAACACCG GGACGCTGGG GGTGTAGTCC GACGAACCCG TGCCGCCCTC

The control of the co

.... -- ALIFET

				_		
32041	CGGTCAGCAC	CGACCTGCTG	GCCTCGATGT	AGAACGTCGC	CGAGGCGTGC 1	PUGAACAUGU
32101	morrosmosco	CACAMCCAMC	ATCTCCTTCA	CCTACTCCTC	GTTCTCGGCA (	STTGCCGGGT
	TUTUGTGGCC	CAGATCGATG	AIGIGGIIGA	0017010010	COCCCCCACC 1	CCTCCCCAT
32161	TCGGTCGGTG	GAACGACCGG	TAGCAGTTCC	GGCCCGCGAA	CTCGGCCAGC	COTCOCAT
32221	CCXXCECCCC	CARCTROCCA	サーサイ しゅっしゅつ	TGGATTCTTC	GAAGICAICG !	100100VV10
32281	COMMOTOCCC	CAACCCACCC	GGATCGATCT	CGGTGGCAGC	GATCAGTTTG (	CTTTCATAC
	CGATGTCCCG	CAACGCACCC	GOVICOVICI	CCCACCGGGC	ACCCAACCCC 1	PTCTACAGCT
32341	TCTCCGCTCA	GAGTTGGTGG	AACGAGGTCA	GCCAGGGGG	AGCGAAGCCC	TCTACAGCT
32401	CCCCTTGGCT	CGTTACCGGC	TTCTCGACCT	CGGTGGATGT	CAAGTAGTCG A	AGATGACTAC
32461	TOCTOCTCCC	CCCATTCCCC	CTCACACTCC	TGATCGCGAG	GTGCGGTGCA (	GGAGAACAGC
	Ticligicoo	GCCATIGCGC	GICHCHCIO	CCCCACTTCT	ACACCATOTO (	CCCTCCTGG
32521	GCGTACGGCT	TGCCCGTCTT	CTTCGAGACG	CCCCMCIIGI	AGACCATCTC (	3000100100
32581	でもででもことののです。	ヤーヤーにっしょっし	AGGCGCTTCC	TGAGCTGCCT	GCGGGGGGGG	AGACIGCIGC
32641	TOCCOLOCOC	CCCCCCCCTT	GCCCGCGCG	GATCCACCGG	AGCCTGCGTA	STGGCCTGCG
	TOUCCACCUC	COCCOCCOII	000000000	NA CECCCCCC	TGTTGACCTT	GCCAGCACG
32701	ATCTGCTGGA	CCTTGTCCAT	CAGCGCCTTG	AACTCGGCGG	IGIIGNOCII	COCCACCACC
32761	TCGGCCGGGT	CCGCACCCTT	CACGACCACC	CACGGGTCGC	TGTACTGACC	GGCGAACTIG
32821	*********	<b>れたれたたたたれてた</b>	CCTCCLCTCC	TGGACCGCCA	TCGAGTCGCG	CACAGCAGCC
32881	WCGIGGCCG	ACACCCCA1C	0010000000	CTCTCACCCT	CAGGAGCCGG	GCCGGCTCG
-	GAGGCCGTCG	TCACCGTCGC	CGACGGCGCG	GICICAGGCI		መድመር እርተሞ እ እ
32941	GGCTGGGCAG	GGGCGGTGCT	CCACGGATCG	TCGTAGGACA	ACTGGTTACC	TITCACITA
33001	TO COCCO TO CO	CCCCTTCCCC	<b>CACTCTTCAT</b>	CGACACCGTC	TTCGALGGCI	TIGGECGCVG
33061	1000000100		ORCA PROCES	CCTACCGAGC	CTGCGGGAAG	CTGGACTCCG
	CAGATTCGTA	CIGCIGCIIG	GIGNIICGCI	COINCOONOO	ChChTCCCCT	CCCACATCCT
33121	GGAAGATCGT	GGAGCCCTTG	ATGAGCCCCG	CGAACCICIT	GAGATCGGCT	GCGHCN1CC1
33181	CCCCCTCCTA	CCCCTCTCCCA	TEGACETTEG	CGGTGAACGA	CACCGCGTTG	TCAGCCCAGC
33241	COOCCICGIA		3300003003	CCTCCTCCAC	GGTCAACTCG	TOGGOTGACT
33301	ACATCTGGTA	GAGCGCCTGG	AACGCCAGGA	GCTGGTGGVG	OJICANCICO	
	CAACGATCTC	CTCGTCCCAA	CCGAGTTCCT	CGACAGCCTG	GACCAACGTG	TCCTTGGTCG
. 33361	CCATCCAAAC	CACCTCGGTG	TTCGGAGCGA	AGAGATCCTT	CTCGATCTCG	TAACCCTCGG
33421	CONTROL	OCCONGCTCG	CCCTTCTCCC	TOTTGAGGTT	GAACCGCACA	CGCCGGATGA
33481	CIGCCAACCI	CCGCAGCICG	GCCATGICGC	TOTAL COLC	TGGCATCTTC	CCCACCCTCC
	AGTACCGCGA	GAAGATCGGG	TGGATCCCCT	CGGAGACICC	IGOCATCITC	TECHCOTOC
33541	CTGTGGGAGC	GATGGTTCGC	TTCTTCACCG	GGACAGGGAT	CCTCAGATCA	TOGGCGAACC
33601	CORCCCCCCCC	<b>ではならかとはなとり</b>	TCACCCCCA	TCTCCCGCAA	GAACTGGGTG	AACCGCTTAT
. 33661		<b>・ かたいりょう かたりょう</b>	・	TGAGGGCCAA	ATAGGAGGCA	ACTCCGAGAT
33721	CICCGGGIGC	CICOGNOINC	CIGCINCCIO	CARCOTCCC	GCTCTTCGGG	TCGGCCACTT
4 4	GACCCACGCC	GATGCGACGG	TTTCGGTCCA	GMACCICCO	9010110000	A MOR COMOCA
33781	CCGAGAACGT	CGCCCGGATC	AGGAATCTCG	TCATCAGACG	ATGCGCCCGG	WICKGGICGV
33841			· CCCCTCACCA	ACGCCGCCAG	GTTGATGTGG	CCGWGGTIGC
33901	3 CCCCMCCC3	ここころがたこれ これ	・ こからる中でかってこ	CCCATGGGTT	GGTGCAGACC	WCCCCG11GG
33961	ACCOUNT COLOR			A CATCCCCGG	CTCTCCGTTG	CGTACGGCTC .
	GCTCACCGAC	GITGGACAGI	GACGAGICCC	ACT CCCCC	CONTCACATA	TOTTOGOGG
34021	CCTCGGAGAG	TGCCTTGAGC	ACTCGGTGGG	CICGCITCIG	CTTGGGCATG	TCCICGCGGG
34081	00100000733		الاستمامات المسامات	- CCAGACGCCA	GAACILGILG	TOVOCCTORY
34141	一 こここれ これがこでず	. <i>CCTCCTCC</i> 3 <i>C</i>	: TCCTCCCCC	TGCTCGCCTL	GAIGIIGAIG	WWCTIGICGW
34201			2002000000	TCCCCCCCG1	CCGGCGCACA	CCGCCGGCCA
	TCTGGTAGTC	. GICCLAGIG	, WICHTCONCH		CATCCCCCCCC	ACCOTGATCC
34261	CAACACACTO	AGCGATGGC	3 TGGTCGACCT	CCATCGCGG	GATGCCGTCG	acci cocccc
34321		, <i>CC3C33C</i> 3T/	2 44466668667	TCTGCAGCAI	CACAGCGAAC	GGCVGCGGC
34381	ACCMACACA (	* ・ 中へでも へぐだる も/	- G46-44467CVC	TRECECCTIO	CGGCCGGATG	COCTCACAT
34441			1 ACCCTCCCC	CTCCCTACTC	CGTGTCGATC	AGATCGACCA
	CGIACACCCC	CIGGINGIA	3 ACCUIGCOU	COMMOCOCOT	CCCACCCCCC	CAGTCGTGGC
34501	GCGCAGCAG	CCAGCCCTC	r CGTGAGTCCT	CONTROCOL	GGCACCGGCC	TO CT CT CC AT
34561	TGTAGTGCT	CGACAGAAT(	G CCTACATCC	TCATCGCCT	GTAGTCGACA	IGCICIGOAI
34621	・・ ペカ ペカ ペカ ペスカリ	アークサイになってってい	C ACCCCCTTTI	CGACCTCGG	GIAGULIIUG	WORTWATAGE
34681			e cccccccc	CCATCAGGC	CATGAACGTG	AACTGGAAGT
	TCGAGTAGT	COCCCCOAC		CONTRACTOR	CANCAGEGE	TGCGCGTTCT
34741	<ul><li>GGTCCGAGA:</li></ul>	r crrcrceee	C CAGCCAGCTA	CCCMGCAGI	GAAGAGGTGC	CTCATCAGAC
34801	MC1 CCCCCC	<u> </u>	A TROUGATION	CCGGCAGCAG	CITGMACTIG	GICHICHONC
34861			W (CAMPECCA YC)	a mamannaan	, GILLUMLAAGA	CONTONATO
34921	COMOCIONA	C COTOTOGAC	C CTTTCCCGC	AGGTTTCCT	CGAGCCGTCA	GGCTTGGTCC
34003	CGTCLACGA	C CCICICONC	C GILICCOCC		CCAAGGGATT	TCGTCAGTCA
3490.	- TGGCGTAGG	T TCGGTTGTA	A ACGAGITCA			TOCCOCCAG
3504	ACTACTTCC	T CTCAGTCAG	T TCGTATCGC	r tgaaatagg	C GTCGGCAGAG	100000000000000000000000000000000000000
3510		こうこうしゅう こうしゅう	a beceecem	r CACCACGCA	CILCULACEIA	MCGMCGCCC -
3516	• -	C C11C1TCCC	とって ないこうかんしつ	T TGGAGGGGT	G CTTGGTCTCG	Trecorracy
2220	TUCTTUCCU	G GUNCHICAG	C COURTECCE		T CCGTAGCCGG	GAGTGAAGCA
3522	- CGATGACCT	T GGTGCCCTT	C TTCATGCCG	W CTICCGIIC	T CCGTAGCCGG	TOGGOGGCTG
7570			بالملف الملاصل الأراح الأرا	G	CILLAGILGE	1 1000000000
2621		A 3.CCTCCGGG	13 36366766	r rrggracag	C TECOMACEGO	CONTCCCC
25/10	]	*************	בוויי מוניה בראייה איני	r accrecer	L CANDANCIC	, GUOUTEGGG
3540	GAACGTCGG	W TOWNSWAT	T TOTOCHIOD	C COMMOMOUS	T CACCATGATO	CCGATGTTCG
- 3546	<u> </u>	G GTAGCCATC	:G CGCAGCTCG	G GGIICICGA	W CHOCHECKS	GCGATGTTCG
2552	1	10 303070000	יא שייייייייייייייי	C ACTITITICGGA	T GILLIGGAAN	3 VIVOCGIOCI
3558	1 TECTECCCC	G ACCATCCT1	G ACGATGACO	T TGCCCTTGI	C GTCCTTCTCC	ACGCCAGCCG
					and the second s	

25611					1000000110	A A CCCCOMMOM
35641	TGATCGCGAT	GATGTTGACG	TGCTCGGTCA	GCGACTTGTG	AGCGCGGAAC	MACCEGITCI
35701	GCCCGCTCTT	ATCCTTCGGG	GAGATCCCGT	CGGTGTAGCG	GCTCCTGATC	GCCTCTGCAT
35761	ACCCCCCCTT	CTGAGCGTCC	AGAGCCTTCA	TCGCCAGCGG	GAGGATGTCG	ACCAGGTACC
35821	ADDCCCCC1	CTCCCCCTGC	A CA C C C T C T T	TCACCTTCTC	CCACCACTAC	TESCTECECT
	GATTGGTCGA	CICCCCIGC	MONOCCICII	DECAL CLACK	CERCCCSSCC	TCATTCCCTA
35881	CCTGGAACAA	GTCGCGGGCC	TTGGCCGCTC	CCGACAGGAT	GITGCGAACC	IGNIIOCOIN
35941	CGTAGTGAAC	TGCCTCACCA	CGGTGCAAGC	TCTCCAGCGT	CTTCTGGATG	TACGGGCTCT
36001	CGAGGTACCA	GACCCACAGC	TCTTGGATGA	TCTCCTCGGC	TGTCAGGTTG	GTCTCCCAAC
36061	CGATCAGCGC	CTTCCGGGTG	CCCCTCCTCA	ACAGCTTGCT	GATGTCGTCG	GTCAAGGCAT
36121	CONTCAGCGC	CIICCOGGIG	OCCCIOCION		ACCTOTOGAG	TCACCTCCTC
		AGGTACTCCT				
36181	CGCGAAGACC	TCGCGGACTT	CGCTGGAGGT	GATCTGGCGC	GAACGTGCGT	TCTTGTGCAG
36241	GTACGGCAGC	TTGGTGGCTG	かてなる このかしてか	GACCTCCCAG	ACTCGGCCGT	CGACCGAGAA
36301	GIACOGCAGC	1100100010	ICOUGITOIN		MOCCOCCOI	COCCOCCACA
	CCGGCCTCCG	ACAATCGGAA	CAAGCTCAGG	CITGACGIGC	TGGCCGTCGA	CCGTCAGCAG
36361	AGCAAAACCA	CTCTGCCAGT	TGGCTGTTGC	ACCCTTGAGG	TACTGAGCTA	GCTTCATGTT
36421	CATCAGGTTG	CCGACCTCCA	TCGACCACAG	CACCTTCTGG	TTGCCGCCGT	AGCCCAGCGT
36481	GTGTGGCTTG	ATGCCCTGGC	CCTCCCTCTC	TCCGATGATC	ACCGACGTGC	CGAACCGCAT
36541	CIGIOCCIIO	TACGCGGTGT	CACCCCACEE	CACCCACTC	CCCACCCAC	CACCCTCCCC
36601	CATCGCGTTG	TACGCGGIGI	CAGCGGACII	CIGCGICACC	COUNCECCAC	CACGGIGGCC
	GTGGGTGGAG	ATCCAGCCTG	GAGCGATCTT	GTAGAACTCA	GGCAGCACGT	CAACACCGAA
36661	CCCGTCGAAG	TCCAGCAGGT	TCTGGAACTG	GAACGAGCTG	ACGTACTCGA	CCAGCGCCGG
36721	GGCGAACTGG	TGCAGGTAGT	CGACTGGCCG	GCGGTCGTGG	TTGCCCTCGT	GGACACCAAC
36781	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	TAGACCTGGC	CCNCCCCCTC	CAGGAACCCC	CCCTTCCACT	CCTCGGAGTC
36841	CGGGCCGTCG	TAGACCTGGC	GCAGCGGCTC	CAGGAACCGC	COCTIONAL	OCICOGNOIC
	GGGCTTGATC	CGCTGAGCGA	ACTCTTCCTT	GGTGCCCTTG	GTCCACCGAG	ACGGGCTCGG
36901	GTAGTCCATC	AGGTCACCGA	TGTGGACGAC	CTCGTCAGGC	TGGGTGTCCC	CGATGTAGCC
36961	GATGACCGCC	TTCAACTGCT	TGCGATCATC	GAACGGAATC	TGGGTGTCCG	AGATGACGAC
37021	GATGCGCTTG	CTCACTCAGC	CACCTCGGTG	AAGGGCCCC	GCATACGTTC	CTCGTGGGAG
37081	GVIGCOCIIG	CTCCTGACCA	OVCCICOGIO.	ANGUGUCUCU	TOTOCTOCA A	CCCCTTCCCC
	CIGGCGITGC	CTCCTGACCA	GCGTCGCTTG	CCCACCITGG	IGIOGIGCAN	CCC0110000
37141	TAGTAGATCC	ACTTCACTCC	TGTGGCGTTG	GTGACGGTCT	TCACATCGGC	AGGAACGTCC
37201	AGCAAGGTGT	CCCACTGGCG	AGGCCCCTTG	GGATACCGCT	CGTCCTCGGG	GAGCTGCATC
372 <del>6</del> 1	TTCTCCAGAA	CGCCTGCGTA	ACCGGCGATG	TCGACCACCG	TGTCCTGGTG	GTAGCCGTTC
37321	TCCATGAACC	GGGCGATCTT	CACCAGGATC	ATCATGACGG	CCACGTCCTC	CGGGGTGAAC
37381	MOCK CCCCCC	GCTTGTACGC	CCCCCSCSCSC	CHCCCCCATCC	CTTCCTCCTT	CTCCTTGGCG
	TCGACGCCGC	GCTTGTACGC	GCCCCACAGG	GICGCGWIGC	GIICGIGGII	CICCIIOGCO
37441	TCCCCSTAGT	CCTGGGCTCG	CIGICCGIIG	ATGATCTCTT	CGGCGGTGGT	CAGAATGCTC
37501	ACAGTCCAGT	CTCCGATGCG	GTGTAGTAGT	CGATCAGCTC	ATCGAGCTGG	TCCGGTTGAT
37561	AGCCGAGGAT	CGGCTTGTGG	GTGTCAGTGA	CGACGACGGG	AACCGACATC	GCGTTGAGCA
37621	CCTTCGTGAC	GTAGTCGTAC	CCCTCCGAGT	TEGCCETGAC	ATCGACTGCG	TCGAAGTCGA
37681	CCTIGGIGAC	CGTCAGCTTG	OCCICCONG!	TOOCCOTONO	CERTACENACEC	CONCECTOR
	TCCCGGCAGC	CGTCAGCTTG	TUTTTGACTC	GCTCGCATGG	·CIIGCAGCCG	GGACGGGIGI
37741	ACACCGTGAC	CGGCGCGAAC	AGCGTTCTCA	CGTGAGCACC	ATCCCAGTCG	ATGTATCGGT
37801	CTCCATACAT	CAGATCCTTT	CCAGCAGAGC	AGCTTTGCCC	TGCGATGTGA	CTAGTGAGTT
37861	GACATCCTCG	CCTTCTGGCA	TCGGGATGAT	TCGGGCGTTC	GGCAGCGTCT	TCGCCACCGA
37921	CCCCCCCAAC	TCCATACCGG	CCTCCTCCCC	CTCCCCCAGG	<b>አጥርጥጥሮልሮ</b> ርጥ	TGCGGTAGCC
37981		TCCATACCGG	COTCOTCOCC	GICGGCCCCC	CCGCTGAGCC	CCACCGTCGG
	CAGGAACAGC	TCTCGGAAGT	ACGGCTTCCA	CITCIGGCI	CCGCTGVGCC	CCVCCG1CGG
38041	CAGCCCACAC	AGCTCGGCGG	TGATCGTGTC	GAGTTCTCCC	TCGCAGATCG	CCATGTCCTT
38101	GCTGTATTTG	GTCAGCGCGT	AGGTGTTGTA	GAGCCGGTCC	TTCTCCCCTG	
38161	GTACTTCGGT	GTGCCACCGT	CGATTCGGCG	ATACCGGATC	GCAGCTACCG	TCCAGTGACG
38221	CCAGGGGGAC	CACCGCATAT	ACCCAATCCC	CAGGCAGCCC	CGGTACATCT	CATGTCCAGG
	GAGTGGGTCG	CUCCOCUTUT	COLCACO	ででででのでするでで	TCCGCTCGGC	CGGCCAGCCC
38341	GAGTGGGTCG	TCCACGAATC	CCAGACCGAA	CCGGCIIAGI		ACCGGGACGT
30341		A: ATACTCGT	CGGCTGGGCT	TCCGGGCAGG	CTTTCTCTGT	
38401	TGCCTCCCAC	At- ATAGGTTC	TCTGCGATTC	GCTTAGCCTC	TGCAAATGTC	ACCTCCTCTT
38461	CGTGACGAAT	GATCGAGATC	ACGTCTCCAC	GGACCCCGCA	GGCCATGCAG	TTGTAGCCCT
38521	GTAGGTCGTA	A CTGA CTGCG	CCAGACGCC	TTTCGTCGCC	GTGGAAGGGG	CACAGGCACT
38581	GIVAGICAIV	WCIONCIOCO	CCRCACCGCCG		CTCCTACCGA	AGAATCGCCC
38641	TGTTCCACTC	GTGGTGGTCA	GGTGGTGGTT	CCCMATCCGG	AT GOT VOCOV	UCCUTTOCC
	TCGCGATGGG	CGAGTCGTTC	ATTCGTCCTC	GTCAAGCTCC	TCGGGAGAGA	GCCCTTCGAA
38701	GATCCCGTTC	AGGACGGCGG	CGAAGCCCTC	GCCGGTCTCC	GCTGCGTCGA	GCATCTCTGC
38761	AATCCTCTTT	GCCATGTTTC	CTCCTGGTGG	ATGTCAAGTT	CGAGACAGCT	TGTCAGCCTC
38821	CACACCACCA	ATGCGCTCCC	CCATCACTO	GACGGCCGCC	GGGTTCAGCA	GGTACTCGAT
38881	ANC TORNOCO	WIRE COLUMN	CONTONCTIO	200000 2000		TCTTCCACAT
	GGCCCGTTTG	AAGAACTCGA	TGCAGTCCCT	CGCCCAGCCC	WOCATATATY	# G# CCCCCCCC
20241	CGTGCAGAGC	AACCCTCGGA	CGATGCCTGT	CTTGTGATCG	TGGTCGACCG	ACAGGCGCTT
39001	CTTCTTACCG	TTGGCTCGCT	GGCAGATGTA	GCACCGACCA	CCTTGGAACT	CGTAGATCTG
39061		MOCCCCCTCX	かいしい かんりゅう かんりゅう		CGGGTCTCCC	AGCTCGTAGA
39121	COMPANIACION		しかしてはかけるかで	ACTACCCCAT	CGTGGCCCTG	GATACTTGGC
	" actacaware	. GICCIONNCI	CICAGIGUIA	HOTHOCOCKT	1	
73181	GTCTCGCGTG	AGCGGGAGCC	CCTGTGCGAC	ACAGTCTTTG	CAAGGCTTCC	GCTTGTGCTT

·						
39241	ACGGTTCTGC	ACCCGGTACC	CCCCNCXCCC	CTTCGCCGCC	CTCCCCC	·
39301	CCCGGTTCTC	CATCACCATC	CCGGAGACCT	CTTCGCCGCC	CTCGGCACGC	GCGTCCTCCT
39361	CCCCCCTTCTC	CATCACCATG	CAGAACCACG	ACAGCAGCCC	TGCCAGGGAG	ATGTAGAAGG
39421	CONCONGRAC	TIGGCCGCTC	ACTTCACCAT	TCCTCGAACC	CACCAGCGAG	A C A C C C C C C C C C C C C C C C C C
	VCCCCTIIC	TUGAGUGGG	TCAGCTCGCG	「「中で女子では中でし	ではなってはなる。	CCSSCMCCSM
39481	GCTGGCGATC	TCGTAGCCGA	GGATCTTGAA	CGACACGTTC	TOTAL COCCORD	COARCICGAI
39541	ATGACGGGAA	TECCECCCCT	TTCCCCCTCA	CONCACGITO	MINGGCGGIC	TCCGAAGTTG
39601	CCGAGGGGGA	ACCCCACACA	CICOGCCICT	CGCATGCAGT	GCCGGGTGCC	GACTGAGTTG
39661	ATCCCACCCC	COUCAGACA	GATGTCCGCA	CCGGCCCTGA	CCATCTCGAT	GTTGCGGAGG
39721	na occarocco	GCTTGCCGTW	GUGTTCCCCAG	- 小しははしかしははか	CCXCCTCCCC	Checkeen
39781	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	COTTONICE	CCAGGCCCCAG	CCCTCTCCC	一年に中での中で3.70~	COCCCCTTCCC
	CCCCCCTGGV	CONCLUTIONG	ACCGGAGAAG	CACCCCTCCT	3 CTC 3 CTC CC	73 1 7 7 7 7 P P P P P P
39841	CAGACCGTGG	TGCGGTCCTT	CCAGATCCCA	GATCCGGTGA	WCT CWO TO C	CAACGCTTCC
39901	TCGCCTCCCA	CTGCAGGGGG	TCCTCCCA	GATCCGGTGA	TCAGTACTCG	CCGCATCAGA
39961	GGGTGGCCAC	CARCOCCO	TCGTGCGACG	TGACCAGCTC	CGCTTCGTAG	ACGCCGTAGC
40021	CCCTCTTCCC	GAACIGGAIC	ATCTGCGCCT	GCTTGTACCC	GAAGGGACAT	TCGTGGACGC
40081	COCTONICOO	GIAICIGACI	CCGTATTTCA	רתיתיכע יויררע ר	<b>では、これでは、これには、これには、これには、これには、これには、これには、これには、これに</b>	MMCCCMcc. c
40141	0110100100	GAGACGITGE	GGGCGAGGCC	CCTCAACTCC	TCCCCCCTCCX	COMMOGRAMA
	OUT CUCOCON	GGCTTGCGG	GATCCGGGCT	רדררפפפדרפ	アルしているからい	CCCMCCLALA
40201	GGTCGGCTTC	GTCTTGATCA	GAGCGCCCAG	CACCTGCTGG	AICCOCIIGI	GGGTCCAGAC
40261	GGGCATAGCG	TTTCCACTCC	TCATCOCCA	CACCIGCIGG	CGCAGTGGGT	TGGTCTTGCG
40321	CCTACTCAAC	CCCCCCCC	CATCIGGAT	CCTTTCCTCG	GTGGCTGTCA	AGTCGGTGTG
40381	COTUGICANO	CULUCUAGG	CATGCGCGCC	CCGCCTGGGG	10000000000000000000000000000000000000	300003000
40441	ONTO LCGGGC	AGGATUGULT	GCGGCTTGAA	GTTGACCTGG	作るたる みつかつぐつ	TO C 3 C 3 C 4 C 4 C 4 C 4 C 4 C 4 C 4 C 4
	TOCGCCWICG	MUCTUCA	TGAAGTAGGA	GACCTTCTCC	GBCBGGCCCB	CC3 1 0000000
40501	CTTGATCCCG	TCCTTGGTCT	TGCAGGTCAC	GTCGAGCTTC	TTTCC3 CCCCC	GGAAGIGCTT
40561	GATTGAGCAC	CGGCCCTGGA	TCTCCACCAC	GTACTTGTCC	TICGACGCGG	TGTCCGCGTT
40621	GATCCGCCGA	TTCATCTCCA	1 CTCGAGCAG	GIACITGICC	GTGATCCCGT	TGAAGAACAC
40681	GGCGTCCCA	TIGNICICON	AGTTGTCAGC	GGCCTTGCTG	ACGTTCTCCG	ATGCGACGTC
40741	COCCATCOCAG	GINCACGCGG	AGAGGCCCAG	GATCGCCGAT	CCCCCCATCA	CTCCCCCCCC
40801	CUTOUTCTIC	LICATUITUG	CTACTTTCTG	TTTCCTCCIT	こうしょう とうかん しょうしょう	TC3 CCC3 S Am
40861	COTIGNICIO	CATAGIGICI	CCGACGAACT	CCNAGGNAGC	CDDCTCTTCTT	COCCROCOD
40001	CCOUCTICCC	CCCICGCITC	TTGACCGTGG	AGACGTTGAG	CATCTCCCCC	CCCIIOCCC
40921	CCGATACTCG	GTGGAGAGTG	ACCATCATOT	CAGGAACACG	CUIGICCOGG	CCGAACCCGT
40981	CCGACAACGG	GATCGGCTTC	WCCCCCCCCCC	CAGGAACACG	CCCGATCTGA	CCTTTGATGC
41041	CGACGCATCA	CCCTCTCTTG	redecerter	TGTGCGGGCC	GGTGACGTGG	TGGAGCCCGA
41101	CCCACATGA	GCCIGICICA	CGGCCCATCT	CGTGTAGGTA	GTCCATCAGC	GACTCCAGAC
41161	CCCUCANCAG	GICGICICC	TUGUTTGAAT	CCCTCCCCAC	CTTCCTCATC	の中で中のの1001
41221		IGGGAAGICC	TCGTACTGCG	CCTCD TO CCC	CCCCBCBCCC	MMCMOOL MAN
	COLCUMENTON	COGTONIGCE	TIGIAGTICA	ACCGGATCGG	<b>CATCTCCTCT</b>	3 CMC3 CMCs c
41281	CTACCGCGTC	CTCGATGTTC	TGCTCGCGAA	CAGCCCGCGT	y COUNCERDOC	WOLCAGICAG
41341	CGCTGAGGAT	GGACACCGAA	CGGGLGLGCG	GGGTGAACGC	AGCICGITCG	AGCGACCATC
41401	ACAACGTCGG	רארכתטבטנה	COCCACACCT	GGGTGAACGC	ATCAGAGTCG	GCCGAGAAGT
41461	CCCCCCCCC	CUCCLICANC	TIGAGCGCGT	AGGCGAGGAC	GAACGCCGAC	TTCCCGGTGC
41521	COOGCCGGC	GUNGALLAGG	ACTAGCTGGC	CTCGTCGGAG.	<b>A 中に中に中れての中</b>	MPCMACAC.
41581	CCCCCCCC	GWCCGGGG	AGCGGATCCC	CCGCCGACCC	<b>ずぐらは3 ずらでりぐ</b>	3 CCC 3 TECES
	-UGGTGTGTU.		CTCGTGGATG	TCATTCACCA	ここでことが ひょうしょか	CTCCTCCCC
41641	OUGUCCUGCC	GGCCCCAGGC	GTCGATCCCC	ACCTCCATCT	CTCTCCCCCC	CITCHAMAAA
41701	GACAGGATCA	TCGGCGAATG	CGTGTGCCCC	TGGATCAGGA	GICICCGGIG	GAIGIGICGG
41761	CTCCACTGGG	TGTGTCGGTC	CALGIOCCCG	TOGNICAGGA	TCTTGCCATC	GTCACGGAGC
41821	AGAACATOTO	TOTOCCOCCO	CICOCIOGIG	TGGTCCCCGA	CGTATGGGAA	GTGGCTCAGC
41881	CJCSCSMCCM		AGCGTCCCCG	TACAGCGGCA	CCCGGATACG	AGCTGCCGTC
41941	OUCUCUTOCT.	COMMEMCE	CCAGTACGCA	CCAACCAGCT	<b>ではてはなべいながら</b>	CCCCTTCITC
42001	0001000000	CWICGIGGII	GCCCAGGATC	ACCCCTTTCC	GGCCTGGCCCC	AMCCCAACAMC
	CUCUCUCU	LAIGIAIL III	Carlot annual Carlot	CXCCCXCXCC		
42061		WELLICAL.	CARCITATION	CACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCXCCCCCCC	
42121	TCGACATCAT	CCGCCAGGTT	CCCCATCCCC	ATCAGCCGCT	CCMGGGIGGC	GTCGTGCTCT
40101		00000001	GCGGWICICC	ATCAGCCGCT	TGTGTCCGAT	GTGTAGATCG
42181	GACCTCAACC	1000000000			•	
44241						
42301	CGGTCGACCA	TECCOLOGIC	roccocorco	TCACGCTCGA	ATCCGCAGCA	GGAATCGTGC
42361	CGATCAAGGC	GTCGTCLLTC	CLUGICGTAG	AGGCTGGGCC	TCACTTCACC	TTCTTCGGAT
42421	CTCGCTGCAT	CTCCTTC	BOCCOACCOG	CGCGAGCCGC	GTGCGTCTCG	GCGTCCAAGG
42481	CICCCIOCAT	CIGGITCATC	AGCCGGGTGC	CGCGCAGCCGC	GAGGATCTTC	ATGGTCGCCC
42541						
42541	GIGACCTCAG	CGACGGGTGG.	TTTGGATCCC	AGTTCGTCAT	CTCTTCCTTC	CCCACCAUCA
42601						
42661	GTTCGGCTCG	ATACCTCTCC	CCTCACCAAC	TOOTOCOGGA	TGAAGTGGCC	GGCCGTTCAT *
42721	AACTCGATCA	CGATCTCTCC	TOCCOCCIONAL	TCCTGCCGGA	TUCATUTCCG	ACCGTCCTCG
42781						
		GOGT COCCAY	CUGAAACTTC	TGCGAGGCGT	ACAGCTCCTG	GTGCCACTTC
				44		

4	42841	GGCTTGTCAG	GAATCGGCCC	CATTTCCACG	TACGTGTAAC	CCGCGTCGGG	GTCGAGTTCG
	42901	AGCGTTTTCT	TGTATTCCTT	CGTGCCTGCC	TTAGAGGGAA	GGTGAGTATC	GGTGGCTGTC
	42961	AAGGTGACCT	CACTTEBALA	CAGGGCAGCT	GTAATTCACA	TCACAGAAGC	CGCATTTGTC
	43021	ANGGIGACCI	ACACCCTCCA	3 CTC3 CC3 GC	CTGGATCCGA	GCCTCGACCT	CATGGAACCT
	43081	WGG11CWGGC	AGAGGCICGA	MOI CACCAGE	CIGONICCON	CCCCCACTCC	CCTTCCCCCTT
		CICGGIGATC	CGCTCCCGCG	TCCAATCGGT	CAGGICGIAG	GGCGCAGTGG	CCTTCGCCTT
	43141	GATGCCCTTC	TTCCCCGCCA	TGAAGTAGTC	GCCCGTCTTC	GGAGCCTCCA	CGTCATAGGT
	43201	CATCGCGACC	GCGAGCGCGT	ACACGCCGAG	CTGGAAGTCG	TCACCCGGCG	AGTTGCCGGT
	43261	CTTGTAGTCC	CGGACTCGAA	GCTCACCGTT	GACCACGACG	ACCGCGTCGA	TGAACCCTCG
	43321	GACGCGGATG	CCGTCCAGCT	CGATGTTGAA	CGGAAGCTCG	ATGGCCGGCT	TGGGCTGTTC
	43381	ACACTCCTTG	CAGTTGGTGT	CTTTCCACGC	CTCCGTAGAG	CAGATCCCTC	GCCCAGGGGT
	43441	AGTCCAGATC	TGCTGGCCCT	TGTCCTTCCG	CCACGCGATG	AACTTCTCTA	CCTGCTCCAG
	43501	TCCAAGGTGG	AACCGGCGCT	CGATGTCACG	CTCACCGTTG	TACGGCCCGG	ACCAAAACCA
	43561	CCACTCGAAG	TTCGGGGTTT	CGTCGCACAG	TECTCCGATE	TCCTTGGCGT	ACTCCTCGCG
	43621	CARCATCTCT	TOTOCCOCTT	CCACCCTCAT	CTCGCGGCCC	TCGGCCAGAG	CCTTCTCGTA
	43681	CACCTCACCC	ACCCTCTCAA	ACCCCCTCCC	CTGCGGCAAC	CACGCCGCAG	GACGAGCCCA
	43741	CACCICAGCG	ACCOLCIONA	ACGCGGIGCC	CTCCCCCCAA	CGTGTGTATT	CCTTC & CTC
		TACCITGICG	ATGCGAGCCA	GCTTGTACGC	CIGCOGGCAA	COLOTOTALL	CAMCCAMCCC
	43801	GCTGACGCTT	CGCAGCGGCA	GCAATGTCTT	GGTGTCTGTC	ACGCAGCGGC	CAICCLICCC
	43861	TTGCCTATCG	TCTCGTTCAG	CGCCCCGTCG	ACAGCGACAC	TGAGCAGTTT	TGCGACCTCC
	43921	GACATGTCAA	TCGGATCCTT	GGGGAATTGG	TCAGCCTGAG	TCATCCTGAG	CACCATCCAC
	43981	TCGGTGCCCT	TGTCGCAGTG	GATCATGGTC	GGATCAAAGC	GAGTTCCCCG	TGCTACGTAC
	44041	TCGACTTTGT	TCGCGGAAAG	AATCAAATTC	GACACAGGCC	GATAAAGTCG	<b>TGAGGTGTCT</b>
	44101	TTTACACGAG	GACTGCGGTA	GACGAGCAGA	ACTGAGACTG	GGTCTTCGTC	CAGTTGGCCC
	44161	TTCCACCACG	CCTCACACCT	CTGCGCGAAC	AGCCACCCTG	GATGATCGGC	GATGACTTGC.
	44221	GGTGAGGTGT	GGACGAGGTT	GTCTGCGAAC	AGCTTTGCGA	GCCGAGTGAG	GGGCACGGGG
	44281	TTTCCTTTCG	TTGCGCGGCC	TEGETTEGET	CACACAACCG	GTCGTGACTT	TTAGGGCTCC
	44341	GAGAGAAGCT	CCTCGATGTC	GTCTGGCCAC	GACCAGAGGA	GTTCACCCTC	GGCGGTGAGG
	44401	ででははではできてい	CCTTCACCC	CATCACCACA	TOTOTOTO	CGATGCCTCG	GGGGACGTAC
	44461	CTGAACCCCC	CCCCCCCCAT	3 CCTTCCT3 C	CCCTCGATGG	ATGGGTCGAA	CTCGAGCACT
	44521	CIGNACCCGC	CGCCGGCCAI	VCCIICGIAG	GOCTCOATOG	VIOGGICOUV	CTCCAGCACI
		AAGTCGTCGT	CGCGGAGCAT	CTTCCACCAC	GACAAIAGGC	GCTTCTTCTT	CTCTTCGGAC
	44581	ATCGTGCGGA	AGCTACCCAC	TCGCATGTAC	TCGCCGTGAT	CCCGGAGCCT	CIGAAAAGCC
	44641	TTCGACTTAT	CGTGAGGTTT	CCGCGTGTCC	CACGGCCAGT	TCTGCTGGAC	GATCTGCCTG
	44701	GTGGTCAACC	GTCCTCCGTA	GGTCTTCTTG	TGCCACGACA	CCGCTTGTCG	AGTCACGCCA
	44761	TACAGCTCTG	CGATTTCGGT	CTGATTAAAC	CCCTTCCTGC	GAAGATCTTC	GATCTCGCTG
	44821	AGAGTGAGTG	GTATTCGGCT	AGGGGCCGGA	ACCACTGCTT	TGTGTTGGAT	TTTGCCGCTC
	44881	ATGTTTCCCT	CCATGAGAAA	GGTGCGTGCG	TCTCCGCCGA	TTACGGAGAC	ATGTTGGTGC
	44941	CTGTCAAGGA	TACCCCTAAT	TTAGTTGCGT	CTGCGGAACC	ATATTCAGTT	GTGTTCCCCG
	45001	ACGCCGTGGC	CGTCTCCCAC	TGGGCGTGGG	ATCGACTGGC	GTTACGCGGT	CGTAAATGTA
	45061	GCGGCCTGCC	CCACTCGGTA	GCAAACCTTG	TGACAGGTAT	CACTTAGGTC	GCCTTCTGTT
	45121	ACACGTTGAC	CTCGGGTTTC	ATCGTCACGA	CTCTCCTTTC	TTAGACAGCC	TCAAGATCGT
	45181	TACACCGGCT	TGCGAAGATG	TACCTTCGCC	TTGAATCCGG	CCCTTGCCAG	CICGAACICG
	45241	<u>እ</u> ዮሮእ ሮሮቸርርሮ	CCCCCCTCTC	CTTCAGGTCG	GACTTCGCCG	ACAGCGGCCC	GACGAACCCG
	45301	<b>ጥ</b> ስ ርርጥር ጥጥር እ	一 中に TA	<b>・ にねののすべのみずの</b>	TCGACGTACA	GCGTGACAGG	GACCACCGAC
	45361	8 8 CTC 8 C 8 C C	ጥሮሮል አጥሮሮሞ	CCCCCTTCAT	CTCGTTGGTC	ACGTCGTAGT	CGTTCAGCAG
	45421	CCACTCCAAC	**************************************	. ጥሮል እርጥሮርጥሮ	CAACTCATCC	TGCTCGAACG	GCGCGGCIC
	45481	GTCATGCCAC	י הדרדדרר ברד	' GGTCGTGGTC	GGCGCGGAAC	: CACTTCCGCA	GATCCTTGAT
	45541	CCCCTCCTCC	* TOCCTCCCC	. AGACGTAGGT	CTCGAGCACG	TCCTCGTACT	CGACGGTCAG
	45601	CCACCAGACG	. CTCATCTC3	、「これにしているます」	ACCTCCGCTI	TGTAGTTCAT	
	45661	・ ロハクレスひれとり	TOTAL	TOGGTTGTAC	TCGTCGTGGC	TGATCTCGCC	AACGATGAAC
	45721	ICCICCIAGI	CARTACCAS	CCARCCCCC	TOTATOOTT	CGGGAATGGG	CTTGGCGTGG
	45741	TUGCUCATCA	CATITUCGAC	COARGCCGCG	NACCACCCE!	GGACCTTGTC	CAGTGAGGTC
	45/61	CCGAACTGCC	AGTCTCGTGA	GCGCCAGCGG	NACCAGAGA TOTAL	CCATCACACC	TCCTGTTTGA
	45841	AGGTGCAGG	ACTGAAACGT	CATGCCTCCC	ANCOUGANCE	COTTOTO	TCCTGTTTGA
	45901	CCTTGACGGT	r GTGGCCTGT(	ATTACTICG	GGATICGGA	, CCC4444C774	AACGTCTTTC
	45061	GCGTCTCGG	CTTGAACTC	g GTGGAGCAC(	CCGAGCACT	COCTITORNI	CGCACTAGCA
	46021		* <b>*********</b> **************************	L TOGGGLOTT	GCCGCCGTC		1010000
	46081		" TTCCCTCITI	ף המדרשרשדה:	L CGGAAGCIC	i CCMIGCIIGA	1 IGIOCOVICE
	46141	CTCCTCCCC	3 <b>1</b>	~	GATGTGCGC	r GCGCTCCGG	WCI CHCHONG
	46201	CCCCCAACCC	~ . @ \$ #@^^#^@	T CCATGATCC	: AGGCAGGTT	3 CCTAGAACCA	1 CCGCCAAGCA
	46261	CNTCNCCNC1	A ACGACGTGC	, <i>გიცი</i> იუუიგ	" CAGCCCGCC	A GCGCGIGGI	CATCACCACA
	46321		P CCCCCTCAC	r crecection	: CCGCTGAGG	I CGIACLGGG	CCGWGGCIIG
	46381	ACCTTCTTC	TGCGAGGAT	CCCCTGGCG	AGAGCCAGC	G CAGCTCGTT	CTTGTCGCCT
	T	W	~ *^^^\\\\				

	46441	CGGTAGAGCA	CCAACGCTCC	CCCGCCGGCC	GATTCCACGG	CCTTGTTCTC	CTCGGCGGTC
			TGACGGCCTG		GCGATCCACG	ACCGGCGGTA	GCTCTTGAGC
	46561	TECCCACCE	TECTETTEE			AGTCGTACTT	
	46621					TCATCTGCGG	
	46681					CGTAGACGTA	
			ATTGGAGCCT				
	46741		GGCTGGCGTA			CCTGAGCCAT	
	46801		GTGCGGCAAC			TGACCCACTG	
:	46861	GGCAGGTCGG	TGGTGTCCAA			CCTGGGCCAT	
	46921	TACTTGGCCA	TCAGCTCGAA	CGCTTTCGCC	TGGAACACAG	CCTCTTCCGG	CGTACCGGCC
	46981	ACGTCTTCGG	CCTGGCGCAG	CAGCTTGGCG	ACCTTGTCCT	GCATCTTCTT	CGTCTTGCCG
	47041	TCGATCATGG		TTCTTCCAGT		GCCCTTGCCG	GGGCGCTTCA
	.47101		GCGGTTACGG			GAGACGCAAC	
	47161		GTCGCTCATC			AGCGGATCTG	
	47221		CGCGGTCTGG			CCAAGACTTC	
	47281					AAGCCTCGTA	
•	47341		CTCGCTGGTC				
			CTCCGACCGC			CGGTGATCAG	
	47401	ACTCTTCTTC				GGCGATCTCG	
	47461		CACTCATCGC			GCCAGCAGTG	
	47521	AGCTCCGATG	TGGCCACCGC	CCTTACCTCC	ACGGCGGGAG	TACTCGCGGT	
	47581	CATGAAGTGG	AACCTCGGTG	AGCCGTCCTC	GTGAACCCAC		
	47641	AGCCCGGTTC	ATCTCCACCG	ACATCGTGAC	GATGATGTGG	TCCCTCTGGA	GCCGAGCCTC
	47701	GGTCTCGGCG	TAGTGGGCAG	CTTGGATTAC	TGCGCCTCGT	GTGGTCATGT	CTTCTCCTTC
	47761	GGTAGATGTC	AAGCTGTCGT	CACCACTCTT	CGACCGGTAT	CGGTTTGTCA	CAGCCAGCAA
	47821		GTTGCTGCGG		CCCACAGCGT	CTTTCGGTCC	
	47881		GAACGGCCAC				TCGTGGACCT
	47941		CTTGCCGGTC		GGTAGTTGTA		
	48001		CACTGGTCCG			GACACCAGCG	
	48061		GCGGAGCTGG			GAACGCCGTG	
	48121					GGAGAGGTAG	
•	. 40121	GCCTTTCAGG	TGTATGTCAA	GCGGCGCGGA	COCCOGNATO	GONGNOGING	ACGCGGTCAG
	48181	CTCCCAGGAA	CGGAGCCTGT	GTGTTGGCGT	GGACGAACGT	GTCGTTCTCG	TAGGGGTTGT
	48241					GATCAGCTCG	
	48301					GCGGCCGGCC	
	48361	CAGCGTGGAC	CACCITICO	CGCTCGCGCC	GIACCIIGIC		COCCERCANCEA
	48421	CACCCTTGGC	GTGGGCCAGC	AGGACGTGGC	CGCTGCGGTG	GATGACTCGA	CCCTTGAAGT
	48481	CTCCCTCCAA	GGCTTGCACC	GAGTACCACG	GCTTGCCCTC	GCGGTGCGTG	CGGTGCAGGT
		TCTTGTAGAC	GAAGACTCGG	ATCGGCTTGG	GAGTCATGAG	ACCTCCAGTG	TGCGAACGGC
	48541					CCGTGCAGGT	
	48601	TTTCAGATAC	ACGGCTTGGT	CGACCGGCTT	GTACTCGACC	CAAGTGACCT	CGACAACCAT
	48661	CCCGTCGATG	ATCGCGAAGT	CTCCAGCGCG	GAGATGGGTG	GGGAATTTGA	TCTCGGTGTT
	48721	GACTACGGTC	: ACAGCTTCGA	AACCTCCCAG	GTACCAACGA	. ACTTGCCGTT	GCGCTTGATG
	48781				ACCTCGAACC		GGCGCAAGCC
	48841	TCGAGGTGGT	CGAGCAGGAG	GCGGCGACCG	GACGCGGTAG	CTTCTCCGGI	CAGCCCGCTG
•	48901		GGACGATGA		TGGTGCCTAC	CCTTCTGCGA	TGTCTCGGGA
	48961					CAGGTGATGT	
	49021		TGGTCTCGC	A AGGCTTCGTT	CCCTCGCC	AGCGTTGTGA	CGAGCCGGTC
	49081	· GATGCGGTCC	TOTTOTOTO	TGTEGETCOLI	GTGGTTGTAC	GCTCAGCCA	TATTGGCGTT
	49141	GGCTCGTTT	TOUTOURAL.	CONCONTICO	T TTCCARTACO	TGGTTAACCA	
	49201		- WORTHOLD	A CCACGAIGG	. IICOMMINOC	GAAGCCTTC	A DETECTOR
	49261	CATGITCIA	CICICCICA	J PAGICGCIG		, GAAGCCIICO	ACTORCOCTCC
		CCTCGTCGTC	GTACGCGCT	GGGTTGCCGC	GCCAGTCGTC	GCGGAGCCTT	TGACCGCIGG
	49321						TAGCGGCAAA
	49381	CCTCGCCGC	C GCAGCGTTG	G CAGTCCCAC	G CGCTGTAAC(	AGGGATCAGG	AAACCTTGGT
	49441	CGTCGGTCT	G ATCAGGGAT	G CGTCGGAAG1	I TCTTGGCAG(	G CATAGCTACT	CCTCATAGAA
	49501	ACTCGTGGT	r Gatggctcg	G TGGGCAGCET	r cgcggaagg?	CAGCCCGTC	TCGTACGCGT
	49561	CCCGGTACG:	r ccagtccgc	G ATGTCTTGG	I AACCAAGACO	Z AAAGGTCTC	GTCATGTAGC
	49621	CGTCCAGCG	C GGCCATCCA	G GTCTCGAAG	C TCATGTCTT(	CCTCACTTC	TTGTGGTCGA
	49681	GAACAGCAC	G TTCCTGCGG	C CGTTGACGC	A CAGACCGCA	A CGGGCACAA	CCGATCCCTT
	49741	GTCGTTGAT	CAGGTCGATG	CTTTGTTGT	T CTCCGGGCA	CGCACCGCC	TCGGAAACTC
٠	49801	GGCCTTGCC	T TTGGCGAAC	G TGGTGTCGA	C GTAGGCGAT	TTGATGCCC'	TGTCTTCCAA
	49861						A GGTTGTCGAG
							C AGAACTGGAC
	49001	A TOTOLOGO	G TOCAGGIAG	A - CAGCC & AAAA	I CIGARCCCI	*	C TGAAGAAGTC
	47307		G ICCCGGATG	A CICGACCCC		A TAGGIGGGG	
	•		and the second of the second o			30 M 4 2 3	

						COCHCCCNAT	CCTTGACGAA
	50041	TCCATCCCAG	TGGATGCGGA	ACAGCTTCGG	AGCCTTGCGA	CGGTCGCAAT	
	50101	CTCGGCGACC	ATCTCGGACA	GCAGCGTCAC	GGTGTCTGTC	AAGTCAGCGT	CACGCAACAG
	50161	TTCCCAGTTG	TGCAGCAGGA	CCGAGCTGAC	AGCCTTGCGA	ACTITCTCCA	GCTTGCCGGC
	50221	GTAGCACACC	TTGGCACAGA	AGGCCGTCGC	GTCCGGGCAG	GAGAAGCCTT	GACCGGAGGG
	50281	CAGGCCGATG	CTGTTGGCGA	TACCTACGGT	GGCGTTGCCG	CCCTTGGTGA	CGTGGACGTA
	50341	GTTGGTGACC	TTGCGGTCGT	TCGAACGCTT	CAGCTTGGCC	ATACCTAGCC	TTCCTTCGGT
	50401	GGCTGTCAAG	TTGTTGGATA	CAAAGCGCCC	CGAGAGGGAG	TCGAACCCTC	ACACCGCGAA
	50461	CCGTCGCGGG	GCCACCGTGC	CTAGTCGATA	GAGGTCACTC	GACTCTCGTG	GACGTAGACC
	50521	ACGGTGTTGC	CTACGTTCAC	CGCGTAGTAC	AGGCCATCGG	CACCTCGTAG	CTTGTGCCGA
	50581	ACCGTGCCCG	ACGTGGCCGT	CATGTCTTCG	CCCCAGTCGG	CGTTAGGTGC	CCAGGTGACT
	50641	CGCATGGTGA	TCCCTTCAGT	AGTCGGTGGC	TGTCAAGTCA	GCGGATACGG	ACGTACCCGT
	50701	TGCCTCGAGC	GACGTAGATC	TTGCCGTCGA	TGTAAACGCG	CTGCTGCTGG	TTCATAATCC
	50761	TATTCCTTTC	GGTGGCTGTC	AAGTCTCAGG	CCCAGCGACG	AGTCGTCGGC	CGGGGGCGGC
	50821	GCACCTTGGG	CGCGTTGGCT	CGCGGTGCCT	TACGGATGGC	GGTGCCTACC	GTGATCTCTT
	50881	CCAACTGGCG	TTCAGCCAGG		GGGCGTCACC	GGGCAGTTCG	ATCTTGTAAT
	50941	CGAAGTCAGT	CCACCCCTTC	AGACCCTTCT	CCAGCTCGCG		CGCGGAGCCG
	51001		CGCAACAAAC		CGCTCTCGCG		CGAACCTCAC
	50161	ACAGCTCAGG	GAAGACTGGC	ATAGTTCACC	CCTTTGGTGG		TGAGCACCAA
•	51121	GGTGCTCAGC		******	AACCCGATAG		ACGTTCTACG
	21171	AGCTCAGGCG	TAGTGGGTAG	TCGGGAATCG	AACCCGATAG	CIICNINGCO	nouttoinco
	51181	GCTCAGCCAT	ACCTCACCGA	TCATTCCATC	GCGCCAAGAG	CTACCCTCCC	GAATGCCGAA
	51241	CCAAAGCTCA	GCATTCGTAA		TCCCCGTGGC	TCAGACAGTA	TCTATCAGAA
	51301	CCTAACCACA	GGTCTACATT	TAGTTATCCG	CAGTGCTCGC	ACTTTAACGG	CATCGAGCTT
	51361	CCGCCGACCC	TCAGTCCTCT	GGCAGCGAAC	TAAAGGTTTG	AGTCGGGCTG	CGGCCCTTCT
•	51421	CGGTCTTGCG	TGATTCTCAC	TCTACCGGAT	GTTTCGGTGG	CTGTCAAGCG	GGCCGTTTTG
	51481	GTGTTGCAAC	GATGCCCTCG	TTTAGCGCCG	CTGGCGTAAT	GCGCTACCCG	CCTGATCTCA
	51541		TTGGTGATGC	TTGCAGCTTA	CCCGATAACC	GGGTGGCTGT	CAAACCGGAG
	51601	CCGGTCCAAG	CCGGATTTTC	ACCGGCACCG	GCACGATCCT	CTCGGATCCG	CCTACCGCCT
	51661	AATCTTGCCG			TGGCCGGGTG		CCTAATCGCA
	51721	TGCTGCTGCG			TTCTCGGTGG	CTGTAAAGGG	CACTACGTGC
	51781	AATTGGTGCC				GCCGCGCATA	GGCTGCTCAC
		CGCTATCCGC		GGACAGTCCC		CGTCGCCCCG	TCGCTGTCGC
	51841	TACGTGCCCG		TGTCGTGCCG		CCGTTGCCGC	TGGTCAGACG
	51901					GGTATGCGTA	
	51961					GCTGGTCAGC	CGTGTGCGTA
	52021					AGGCCGGCTC	TCGCATCGTC
	52081						
	52141						
	52201	CTCGCATCGC	ATCGAGTGTT	TGCTGTGTCT	CTCATCGTCG	CWGGICWGWW	GGGGTAGGGG
	C0061						

15

20

25

It is known that during the establishment of lysogeny, the L5 genome becomes integrated into the mycobacterial chromosome and the attachment site (attP). Integration-proficient plasmid vectors have been constructed which efficiently transform both fast-growing and slow-growing mycobacteria through stable integration of the plasmid sequences into the bacterial chromosomal attachment site (attB).

Because the L5 sequence is now known, and because L5 has been previously characterized, the use of transcriptional promoters with this mycobacteriophage may be evaluated efficiently, and host synthesis inhibition may also be evaluated efficiently.

Figure 1 represents the genome organization of the entire L5 genome. DNA analysis has indicated that the L5 genome is organized into a right and left arm with the attachment site and integrase at the center of the genome. The integration functions have been successfully employed to construct integration-proficient vectors for mycobacteria.

Part of the L5 genome is not essential for mycobacteriophage growth. It has been demonstrated that all or most of the gene 62-61-60 can be deleted without affecting the cycle of the L5 phage. Therefore, there is a suitable region in the L5 mycobacteriophage for the insertion of reporter

10

15

20

25

genes. It is critical that reporter genes be inserted into non-essential regions of the mycobacteirophage.

Otherwise, the mycobacteriophage will be unable to survive and replicate.

The L5 mycobacteriophage may have introduced therein promoter gene 62 fused to reporter gene lacZ, and this reporter mycobacteriophage will be capable of rapid diagnosis of mycobacterial infection and accurate assessment of mycobacterial strain drug susceptibilities.

mycobacteriophage which Another be successfully used to produce the reporter mycobaceriophages is the mycobacteriophage TM4. has been used to construct a first generation reporter mycobaceriophage, and has the ability to discriminate between M. tuberculosis and BCG. A shuttle plasmid may be employed with TM4, and may be useful in the recombinant and other construction of mycobacteriophages. Unlike L5, which is a broad mycobacteriophage, TM4 is host-range species-specific mycobacteriophage. However, not as well characterized as the L5 mycobacteriophage, and therefore it is more difficult to analyze its functions.

DS6A is a mycobaceriophage that has been found to be specific for the <u>M. tuberculosis</u> complex of mycobacteria. It has been shown to inf ct both

10

M. tuberculosis and BCG. It has been demonstrated that DS6A can infect over 3,000 different types of Current efforts are under M. tuberculosis strains. way to develop DS6A shuttle phasmids containing Firefly luciferase genes as the reporter molecule. is possible that a combination of different increase needed to mycobacteriophages be may ability the then increase specificity distinguish drug susceptibilities. DS6A grows on BCG and M. tuberculosis, but does not grow on M. smegmatis.

In anticipation of the need for a diverse set of mycobacteriophages that can effect a limited range of mycobacterial cells, a total of more than 50 unique mycobacteriophages have been collected inventors. new the by isolated 15 and mycobacteriophages have been isolated from soil samples from India, France, England, Israel, Tunisia, In addition, another 30 Carville, LA and New York. mycobacteriophages from both the Centers for Disease Control in Atlanta and the World Health Organization 20 Amsterdam were Reference Laboratory in Phage The characterization of the nucleic acid collected. content of the phage particles of 30 these of mycobacteriophages have revealed that all of the mycobacteriophages contain double stranded DNA whose 25 genome sizes range from 45 to 100kb as sized on pulsed field gels. Restriction analysis has shown that all

10

( :: :

of these mycobacteriophages are different, except that mycobacteriophages from France had a considerable similarity to the L5 mycobacteriophage, which was originally isolated in Japan. The host range of the mycobacteriophages varies greatly, some being able to infect only M. smegmatis and others **BCG** infect M. smegmatis, and to able being These M. avium. not but M. tuberculosis, mycobacteriophages may be developed into reporter mycobacteriophages and cosmid cloning systems, and may provide a source of useful transcriptional translation initiating sequences, transcriptional terminators, or host-range specificity genes.

In addition, the choice of reporter gene and

its method of expression are critical. It is

necessary to choose a reporter gene whose product

would not normally be found in clinical samples, but

whose product is also easily detectable.

Luciferase reporter genes have been used in including biological systems, diversified 20 many E. coli, cyanobacteria, phytopathogenic bacteria and The presence of luciferase reporter genes can be detected by the emission of photons in the presence of a substrate, such as luciferin or decanal 25 decanal. Luciferin and 10 may 2 may 2 detection of mycobacteria, and ther by allow for th Elevel - The I - the gene products, such as photons. Sinc one molecule of

15

the luciferase gene product can yield 0.85 photons of light, it is the most sensitive biological reporter The preferred reporter genes of this molecule known. invention are luciferase reporter genes, such as the Firefly <u>lux</u> gene (FF<u>lux</u>), the <u>Vibrio fischeri lux</u> genes and the <u>Xenorhabdus luminescens lux</u> genes, as as the <u>E. coli</u> B-galactosidase (<u>lac</u>Z) Luciferase genes, especially the Firetly <u>lux</u> gene, geneate a high amount of luminescence activity. generate photons, the detection of which is simple and sensitive, using commercially available luminometers that can detect 100-1000 molecules of luciferase with a linear relationship to enzyme concentration. addition, it is unlikely that clinical samples will contain significant levels of endogenous luciferase activity.

In choosing transcriptional promoters to be mycobacteriophages, it into introduced the desirable to use strong promoters since this will increase the sensitivity of the system. In addition, it is important that the promoter be active following best The mycobacteriophage infection. candidates currently available are the BCG hsp60 promoter and the L5 gene 62 promoter, which are of comparable strength. The hsp60 promoter gives good plasmid expression luciferase ·of luciferase levels recombinants, lower

10

possible that the reason for this is that the hsp60 promoter is shut off by the TM4 enzymes following infection, thus producing only a modest level of luciferase. The gene 62 promoter may behave in a similar manner with the TM4 phage since the gene 62 product is a good candidate for the L5 repressor and is expressed at high levels in the absence of other mycobacteriophage functions. Knowing the sequence of the mycobacteriophage used will help in identifying, characterizing and cloning the appropriate promoter to be used in the reporter mycobacteriophages of this invention.

There are several methods which can be introduce the reporter genes 15 utilized to into mycobacterial transcriptional promoters species-specific mycobacteriophages. One method is the utilization of shuttle phasmids. When utilizing shuttle phasmid technology, it is necessary to know the sequence of the mycobacteriophage so that the 20 reporter genes are inserted into non-essential regions of the mycobacteriophage. Insertion of reporter genes permits non-essential regions mycobacteriophage to survive and replicate. In order to use the shuttle phasmid methodology, 25 necessary to first generate a cosmid library of large DNA fragments double-stranded recombinant

mycobacteriophage. This can be done using cosmid cloning in E. coli. Next, the cosmid library is introduced into the mycobacteria of interest to select for cosmids which have been inserted into

non-essential regions of the mycobacteriophage. The shuttle phasmids, which consist of the E. coli cosmid, the reporter genes and mycobacteriophage promoters, may then be characterized. Shuttle phasmids can be propagated in E. coli as plasmids, and propagated in mycobacteria as mycobacteriophages.

A second method of introducing the reporter genes and transcriptional promoters into mycobacteriophages is by homologous recombination or PCR. First, non-essential regions of a mycobacteriophage must be determined. Again, in order 15 to do this, it is necessary to know the sequence of the mycobacteriophage. Consequently, L5 is an ideal phage to use with this method as its genome has already been sequenced and characterized by the Next, plasmids are constructed wherein 20 reporter genes hooked to transcriptional promoters are flanked by mycobacteriophage non-essential region sequences in mycobacterial plasmids. Then, homologous recombination systems or PCR may be utilized in M. smegmatis or E. coli to perform gene replacement whereby the plasmid constructs containing the reporter genes ar put into mycobacteriophages

10

20

25

A third method of introducing reporter genes and transcriptional promoters into mycobacteriophages is by use of transposons. For example, transposon IS1096 may be utilized. In order to use this

methodology, reporter genes and transcriptional promoters are put into transposons, and the transposons containing the reporter genes and transcriptional promoters are delivered on plasmids in mycobacteria. Next, it is necessary to grow up the

mycobacteriophages on a strain such as M. smegmatis, which strain contains the transposons. At certain frequencies, the t: nsposons will hop into non-essential regions of the mycobacteriophages, thereby introducing themselves therein. The

mycobacteriophages are still viable, and contain the reporter genes and transcriptional promoters.

A fourth method of introducing reporter genes and transcriptional promoters into mycobacteriophages is by debilitated phages packaged into phage heads and tails (phage particles). To utilize this methodology, it is necessary to develop helper phage systems which allow for pieces of DNA containing pac sites to be packaged. These helper phages allow for the synthesis of head and tail genes at will in mycobacteria, prevent themselves from being packaged into phage heads and tails, and facilitate packaging of pacmids into phage heads and tails. Helper phage systems may

15

20

mycobacteriophage. The L5generated from the the into is helper phage genome the which time the chromosome, at mycobacterial mycobacteria are grown up. Next, pacmids which comprise phages which have pac sites, reporter genes, transcriptional promoters and mycobacterial replicons are transformed onto the mycobacterial strain. production of head and tail proteins may be induced, for example, through an increase in temperature, and the pacmids are then packaged into phage heads and The L5 genome has cohesive (cos) termini. This suggests the possibility of constructing cosmid vectors, which could be packaged through the cos sites into L5 particles either in vivo or in Then, a large number of genes could be easily and efficiently delivered to mycobacteria.

Packaging into phage heads and tails may also be utilized in a fifth methodology wherein the pacmid is a plasmid. The methodology is similar to the methodology wherein a debilitated phage is used, however, instead of using phage pacmids, the pacmids comprise plasmids which have pac sites, reporter genes, transcriptional promoters, and plasmid replicons.

25 Finally, direct cloning using recombinant DNA techniques in vitro may be used to introduce reporter genes and transcriptional promoters into

10

15

20

25

(

mycobacteriophages. This methodology consists of ligating a mycobacteriophage, identifying or introducing unique restriction enzyme sites in non-essential regions of the mycobacteriophage,

cleaving the mycobacteriophage with the restriction enzyme sites, and cleaving DNA which encodes the promoter and the reporter gene so that it has the unique sites flanking it on either side. Next, ligation is set up in vitro between the cleaved mycobacteriophage with the unique restriction enzyme sites and the reporter gene cassette. The result is a the molecule which consists of circular DNA mycobacteriophage, the reporter genes and the transcriptional promoters. The circular DNA may then be electroporated directly into mycobacteria.

#### EXAMPLES

# Expression of Reporter Gene lacZ and FFlux in Mycobacteria

A promoter probe vector was constructed which truncated E. coli B-galactosidase incorporated (lacz) gene as a reporter probe into a shuttle plasmid vector that replicated in either mycobacteria the Random DNA fragments from three E. coli. mycobacteriophages Ll, TM4 and Bxbl were cloned into a unique BamHl site immediately upstream of the lacZ and screen d for their ability to produce B-galactosidase. This established that <a href="mailto:lac">lac</a>Z could be

as a reporter gene in the mycobacteria, and identified the DNA sequences which could effectively M. smegmatis and both in genes foreign express B-galactosidase activity could be M. tuberculosis. detected from lysed cells using OMPG, or from unlysed fluorescent X-gal either cells using methylumbelliferyl ß-galactosidase derivative. The promoter hsp60 gene highly expressed the <a href="mailto:lac">lac</a>Z gene in both M. smeamatis and BCG.

into pMV261 cloned was 10 The gene FFlux downstream from the hsp60 promoter in plasmid pYUB180 (see Figure 2), which plasmid was shown to express the FFlux gene in M. smegmatis, BCG and M. tuberculosis The expression of the FFlux gene was detected by observing luminescence of mycobacterial clones 15 containing the cloned gene in the dark room, and verified use in photographic film. This demonstrated that the luciferase was expressed in the mycobacteria, and that luciferin, the substrate used, was able to penetrate mycobacterial cell walls and yield photons expressed by the mycobacteria.

# Detection of Photons In Mycobacterial Cells Expressing FFlux

The expression of FF<u>lux</u> from the plasmid

25 pYUB180 in <u>M. smegmatis</u> provided a model with which to

determine a minimal number of individual cells

Confo lone liquitae #14/5

15

20

25

(i.v.

detectable with the luciferase assay. M. smegmatis containing pYUB180 were grown in the presence of kanamycin to ensure that every cell contained the The cells were diluted 10-fold serially and the amount of luciferase activity was determined using Figure 3 shows that the amount of luminometer. from 5 X 10<sup>7</sup> cells approached activity luciferase 108 this level of luciferase units, though at activity the luminometer was unable to vield However, the activity decreased 10 . accurate measurement. in a linear manner down to 1200 units for 500 cells. Hence, 5000 cells expressing the FF<u>lux</u> gene can be clearly discerned above the background measurement, which approaches the number of cells that one would expect to observe in clinical samples.

Distinguishing Drug-Resistant Mycobacteria From Drug-Sensitive Mycobacteria Using Luciferase Activity

Since Firefly luciferase activity requires ATP, and ATP is produced only by living cells which are metabolically active, luciferase is a powerful indicator of the metabolic abilities of a bacterial Since anti-tuberculosis drugs are likely to significantly decrease the metabolic activity of a cell, the measurement of luciferase activity should distinguishing sensitive means of provide а drug-sensitive drug-resistant mycobacteria from mycobacteria.

15

20

25

First, the kinetics of the production of luciferase activity of <u>M. smeamatis</u> containing pYUB180 following the addition of streptomycin, isoniazid, ethambutol, rifampicin, ciprofloxacin, novobiocin or cyanide, added at levels that inhibit the growth of <u>M. smeamatis</u> in plate assays, was measured.

As shown in Figure 4, Panel A; the levels of luciferase production were 100 to 1000 times less at eight hours after the addition of the drugs compared to the untreated control.

Next, this approach was used to distinguish drug-resistant from drug-sensitive mycobacteria. transformed pYUB180 deposit was novobiocin-resistant streptomycin-resistant or. production the by Photon M. smegmatis mutants. compared the drug-sensitive parent was novobiocin-resistant streptomycin-resistant or The drug-resistant mutants continued to mutants. produce luciferase activity levels comparable to the untreated patent in the presence of the appropriate In addition, the drug-resistant mutants antibiotic. produced 100 to 1000 times more luciferase activity than the drug-sensitive parent (see Figure 4, Panels B Hence, a luciferase-based assay may be used and C). to determine mycobacterial drug susceptibility.

10

15

20

#### Construction of TM4 Reporter Mycobacteriophages and Detection of Photons Following TM4:: lux Infection

introduce developed to The first vectors recombinant DNA into mycobacteria were shuttle phasmid Shuttle phasmids have the ability to phage vectors. replicate in E. coli as cosmids and then replicate in mycobacteria as phages. Shuttle phasmids of TM4 which contained the FFlux and lacZ genes transcribed from hsp60 and L1 promoters, respectively, were constructed (see Figure 5).

A deposit of the shuttle phasmid (reporter contains which mycobaceriophage) phAE39 mycobacteriophage TM4, cosmid pYUB216, reporter gene FFlux and promoter hsp60, was made with the American January 12, 1992 and Type Culture Collection on catalogued as ATCC #75183. When the TM4:: lux shuttle phasmid phAE39 was mixed with M. smeamatis cells, detected within activity could be luciferase minutes of incubation, and continued to increase slightly over the next 4 hours (see Figure 6). results show that the TM4:: lux mycobacteriophage is FF<u>lux</u> gene into introducing the of capable mycobacterial cells, and that the FFlux gene can be expressed in mycobacteriophage-infected cells. Figure 25 7 represents a flow chart for cloning different promoters into the TM4:: lux shuttle phasmid phAE39.

A deposit of the shuttle phasmid (reporter

10

15

20

25

mycobacteriophage TM4, cosmid pYUB216, reporter gene lacZ and promoter L1, was made with the American Type Culture Collection on \_\_\_\_\_\_\_, 1992 and catalogued as ATCC #\_\_\_\_\_\_. The TM4::lacZ mycobacteriophage formed bright blue plaques when plated on media containing X-gal.

## Construction of the L5 Reporter Mycobacterophage

Strategies for construction of the recombinant L5 mycobacteriophage may be investigated. The possibility of using the shuttle phasmid approach starting with L5 deletion derivatives, in which the size of the genome has been reduced, may also be explored. Initially, the largest gene 62 deletion available should be used. However, other deletion derivatives in which more of the gene 62-61-60 segment is lost should also be isolated. Another approach would be to attempt to introduce genes by homologous recombination with plasmids. Still another approach would be to transpose lux genes onto L5 using either the mini-Mu in vitro transposition system or a mycobacterial transposon such as IS1096.

Recombining reporter genes from recombinant plasmids onto L5 using a double recombination event may also be performed. This involves first constructing a recombinant plasmid that carries a reporter gen (lacz may be more suitable) inserted

10

15

20

into such that both the upstream gene 62 downstream parts of gene 62 are present. Advantages of this approach are that lacZ can be easily detected in agar media, that gene 62 is not an essential gene, and that lac is efficiently expressed from a promoter immediately upstream 62. of gene An L5 mycobacteriophage lysate may be prepared by growth of plasmid-containing strain and recombinant mycobacteriophage progeny identified by plating the M. smegmatis lysate on wild-type for individual plaques on agar containing the indicator X-gal.

This recombination approach may be expanded to introduce other gene or DNA segments of genome. For example, it should be possible to add luciferase genes from FFlux in an identical manner, provided that packaging limits are not exceeded. addition, inclusion of polylinker containing restriction enzyme sites unique for L5 would open the way for construction of L5 recombinants in vitro. Similar genetic strategies may systematically reduce the size of the L5 genome deletion of non-essential sequences.

Transposition offers an alternative method for the construction of reporter mycobacteriophages. A transposition system which is available is the mini-Mu in vitro transposition system. This is a defined biochemical reaction in which a mini-Mu transposon

carrying the desired gene is transposed onto the phage genome using purified MuA and MuB proteins. Similar transposition experiments have been tried with L5, but few L5 mini-Mu derivatives have been isolated. It is possible that this is due to the relatively large size of the transposon used. It is necessary to first construct a small Mu transposon which contains the reporter gene, a promoter and the two Mu in order for these experiments to be successful.

Development of L5 <u>in vivo</u> and in vitro Packaging Systems

era (1994), in [a. pladde of one poets

g cosmids and packaging systems provide the efficiency of mycobacteriophage infection with the of ability inject large segments to . Analogous mycobacterial non-mycobacteriophage DNA. constraints overcome packaging systems would encountered with recombinant mycobacteriophage genomes and allow the introduction of multiple copies or types genes into mycobacteria, potentially reporter enhancing the sensitivity of the assay. In addition, they would help overcome any problems with host synthesis inhibition.

The development of L5 cosmids and packaging systems is dependent on the finding that the L5 genome contains cohesive termini. The g paradigm suggests that a relatively small region of DNA (approximately 500bp) around the cos site (in the ligated form) is

15

20

necessary to promote packaging. The first series of experiments with L5 would therefore be to identify the segment of the genome required for packaging by constructing a series of plasmids containing the L5 cos site and surrounding sequences. Cos activity may be determined by preparation of an L5 lysate on plasmid-containing M. smegmatis strains, followed by identification of antibiotic-resistant the lysate, by transduction of transductants in the that plasmid This assumes M. smegmatis. assay 10 multimers of a total size of approximately 50kb are present in the cell and will be packaged. not such multimers has the presence of demonstrated directly, they are likely to be generated 15 homologous recombination system by the If this assay should fail, cosmid M. smegmatis. vectors which contain both L5 g cos sites may be Insertion of 40-45kb of DNA (as in the constructed. of cosmid libraries) followed by construction packaging in vitro and infection with E. coli will 20 generate 50kb sized molecules containing L5 cos site. These should be isolated from E. coli and introduced Assuming that by electroporation into M. smegmatis. one of these approaches is successful, it would then be possible to define a small segment of L5 required for packaging.

The construction of in vivo cosmid packaging

systems is a particularly attractive idea since it has Thermoinducible in E. coli. very useful lysogens of L5 may be suitable for in vivo packaging of L5 cosmids without further modification, since temperature-sensitive may be а prophage excision packaging extrachromosomal Efficient of event. cosmids present in the lysogen may be achieved by simple induction and growth at 42°C.

It is possible that some process other than temperature-sensitive in lysogen excision 10 If so, it will be necessary to further induction. debilitate the prophage in order to prevent packaging of the prophage. There are a variety of ways to accomplish this. For example, the excise gene could be deleted (using a recombination 15 strategy similar to that described above) such as to prevent excision. Another approach is to damage the cohesive termini (by exonucleolytic digestion) of an construct and derivative L5 \_ thermoinducible defective lysogen. A combination of approaches may be desirable, since even if prophage excision is a temperature-sensitive process, the destruction of cos might effectively reduce the background of spontaneous mycobacteriophage release.

Construction of <u>in vitro</u> packaging systems will follow similar lines. Extracts may be prepared from thermoinducible strains with non-packagable

prophages and assessed for their ability to package exogenously added L5 cosmid or mycobacteriophage DNA. Optimization of conditions should follow both empirical biochemical approaches and the well-established g systems. For example, it may be necessary to supplement the extracts with purified mycobacteriophage products such as the terminase or the tape-measure analogues (genes A/Nu and H respectively), neither of which have yet been 10 identified.

#### Construction of Novel Shuttle Phasmids From Any Mycobacteriophage

Although mycobacteriophages L5 and TM4 can be used in the development of diagnostic luciferase and B-galactosidase shuttle phasmids, there may be other 15 mycobacteriophages, such as the mycobacteriophage DS6A which only infects BCG and M. tuberculosis strains, that might prove to have a more useful host range for clinical isolates. Diagnostic luciferase 20 mycobacteriophages from these other mycobacteriophages be developed by using the shuttle methodology described herein that has been proven successful for constructing mycobacteriophage vectors from both TM4 and phage L1.

#### Isolate Mycobacteriophage L5 and TM4 Mutants to Infect the Maximum Number of Clinial Isolates

For th diagnostic luciferase mycobacteriophage system to have maximal use in the clinical laboratory,

15

20

25

be essential that to develop a it will diagnostic mycobacteriophages that can infect any clinical isolate and possibly distinguish and BCG. M. avium M. tuberculosis from TM4 and L5 appear to have the mycobacteriophages ability to infect a large number of M. tuberculosis TM4 is very closely related to phage 33D, a isolates. mycobacteriophage that has been found not to infect define every M. tuberculosis isolate used to mycobacteriophage typing schemes for M. tuberculosis However, this mycobacteriophage does not isolates. infect BCG. TM4 has been found to be almost identical by DNA hybridization and restriction analysis to 33D, and it shares the host-specificity with 33D in that it infects M. tuberculosis, but fails to infect BCG. mycobacteriophage L5 appears to share the same receptor as mycobacteriophage D29 which receptor has been previously shown to infect a very large number of L5, unlike 33D or M. tuberculosis isolates. infects all three morphotypes of M. avium including a wide range of serovariants.

If L5 or TM4 are found not to infect certain M. tuberculosis isolates, it may be possible to isolate mutants of these mycobacteriophages which plaque on the particular isolate. The inability to plaque on a particular isolate could result from the lack of a mycobacteriophage receptor or be the result

10

15

**(**:..

of lysogenization of the isolate with a homoimmune with altered host Phage mutants bind specificities or mutants which no longer repressor (equivalent to virulent mutant of g) have been isolated in other systems. Variants of TM4 which efficiently infect BCG have been isolated at can frequencies of 107. Previous work has demonstrated that 33D, similarly to TM4, can not adsorb to BCG Host-range variants of TM4 which not only cells. plaque BCG, but also still plaque M. tuberculosis have been isolated. Similar strategies for M. tuberculosis isolates which are uninfected by L5 or TM4 may be used.

#### Detecting the Presence of M. tuberculosis in Clinical Samples

The combined sensitivities of luciferase and should permit the mycobacteriophage infections previously undetectable levels of detection of M. tuberculosis cells in sputum, blood samples, preliminary number of cerebral spinal fluid. Α studies to optimize the detection of M. tuberculosis 20 cells in a variety of body samples will be performed.

#### Detecting M. tuberculosis Grown In Primary Human Macrophages and Macrophage Cell Lines

As a model system for optimizing detection of M. tuberculosis in infected monocytes and macrophages, 25 primary human monocytes which have been purified by ' Santa Care Comment adherence for 1 hour or primary macrophages which have

CONTROL OF STATE AND A CONTROL OF STATE OF THE

• 5

10

20

cultured for 6 days in microwells will be infected with M. tuberculosis H37Ra varying of cells initially multiplicities. The number infected will be determined microscopically, and then at various periods of time from 2 hours to 30 days, the cells will by lysed by non-ionic detergent NP40 which has no effect on viability of mycobacteria, concentrated by centrifugation, plated for viable organisms and infected with the luciferase plasmids. Quantitative studies at different moi's and with varying numbers of infected cells will indicate how few bacilli/cell and bacilli/specimen can be detected.

The inability of M. tuberculosis cells isolated macrophages to be infected with diagnostic shuttle phasmids could result from either the absence of the expression of the mycobacteriophage-receptor or the masking of the receptor with a membrane from a phagosome of the macrophage. The level of expression of phage receptors may be regulated by the environment in which the host cell is grown. For example, the g E. coli is induced by maltose of repressor by glucose. Studies to identify repressed mycobacteriophage L5receptors for Similar studies for mycobacteriophage TM4 initiated. By identifying the genes will also be performed. encoding the receptor, it is possible to assay gene mycobacteriophage receptor of the repression of

10

15

M. tuberculosis cells when grown in macrophages by hybridization for the mRNA synthesis. If the receptor is not expressed in macrophages, it may be necessary to use a mycobacteriophage which recognizes a receptor that is constitutively expressed.

If the receptor is masked by a membrane of the macrophage, the cells isolated from macrophages may be treated with a variety of different detergents to find treatment that would allow infection of the M. tuberculosis cells with the mycobacteriophages. necessary to cultivate Again, it may be detergent-treated macrophages in broth for a few generations to gain expression of the receptors. assays to determine the infectability of macrophages from mycobacteria include not only the luciferase assay for the TM4:: lux mycobacteriophages, but also which infectious centers assays free removed and mycobacteriophages are mycobacteriophage-producing cells are scored mixed plating on a lawn of M. smegmatis. This assay would be useful since infectability can be scored even if there are insufficient M. tuberculosis cells to It is important to re-evaluate form a bacterial lawn. specificities οf all of the the host range mycobacteriophages in Free this assay. 25 mycobacteriophages can simply be removed through the use of specific anti-mycobacteriophage antibodies.

Detecting M. tuberculosis in Sputum Samples

patient infected Sputum from mixture of M. tuberculosis contains M. tuberculosis cells, mucoploysaccharide, free macrophages containing M. tuberculosis cells and a Sputum samples from 5 variety of cellular debris. patients thought to have pulmonary tuberculosis may be used for a study in which various numbers of M. tuberculosis cells are added to sputum samples or few organisms by acid-fast found to have no 10. staining. A variety of methods can be used to treat sputum samples so as to liquify the mucous decontaminate the specimen under conditions in which bacteria other than mycobacteria are phasmids, specificity of the Because of the decontamination may not be as important as preserving 15 mycobacteriophage receptors. Nonetheless, the sputum samples may be treated initially with 2% w/v NaOH for 30 minutes at 37°C or with 0.5% N-acetyl cysteine + 1% NaOH. Alternatively, the sample may be treated with a variety of hydrolytic enzymes, such as 20 collagenase, to help dissolve the sputum sample. If mycobacteriophage receptors are carbohydrates possibly sensitive to these conditions, other conditions may be utilized or the cells will be cultured 3-16 hours to 25 allow recovery of infectivity before mycobacteriophage infection.

ส์ จาก และ นัก และ กรุงทำสูงหลักของของโดก จาก และ คือ สมมาณ และ โดย ค.ศ. โ

reignal mykrat lilijas ir ingini i

10

15

20

25

( \*...

#### Detecting Mycobacteria In Blood Samples

Tuberculosis has been known to have If the sensitivity necessary to detect bacteremia. 100 to 200 M. tuberculosis cells in a ml of sample can obtained, levels of bacteremia in tuberculosis patients which were not previously observable may be cells should purified observed. White be Ficoil-hypaque and lysed with 2% NP40, 1% SDS or freeze-thawing in the presence of DNAse to liberate The pellet should then be intracellular mycobacteria. luciferase infected with the diagnostic mycobacteriophage, or if only few organisms present they can be concentrated by filtration onto filters, and filter areas cut out and infected.

# Assuring Specificity On a Variety of Clinical Isolates and Species; Assessment of False Positives and Negatives

The luciferase assay may be optimized such that positive correlations of M. tuberculosis infections as indicated in the clinical lab may be obtained. The recombinant mycobacteriophages may be tested ascertain the range of specificity that they have for other mycobacteria, and for the closely related genera Actinomycetes Corynebacterium, and Norcardia, These strains may be obtained from the strains. A number of blinded tests including negative controls, M. tuberculosis-infected patients, samples

from patients infected with M. avium, and infected with other non-mycobacterial pathogens may be performed to ascertain the range of specificity.

assess the to rapidly The ability 5 of M. tuberculosis isolates to susceptibilities isoniazid, ethambutol, rifampicin, pyrazinamide other antibiotics will have a major impact on the After the tuberculosis patients. οf treatment isolation of M. tuberculosis cells from a sputum sample, which may take several weeks, the assessment 10 of drug-susceptibilities may take an additional 2 to 9 Diagnostic reporter mycobacteriophages may allow for evaluations of drug-susceptibilities at the time a sputum sample is collected. Alternatively, this approach would shorten the time necessary to of purified drug-susceptibilities up from clinical M. tuberculosis colonies grown samples.

#### Luciferase Assays for M. tuberculosis Cells in the Presence of Drugs

20

经收益债金 化氯化氯化 医胸部切除术 经成本证据 网络沙洲

The results of the experiments suggest that by using luciferase as an indicator for the metabolic ability of the cell, it may be possible to define conditions which will enable us to distinguish mycobacteria from drug-sensitive drug-resistant mycobacteria. To test this hypothesis, isolated

25

10

15

Carri

mutants of M. tuberculosis H37Ra which are resistant to isoniazid, rifampicin, ethambutol, or pyrazinamide would be used to generate a set of cogenic mutants. These independent mutants and the parent strains would be transformed with pYUB180. Luciferase activity will be assessed in the presence and absence of drugs in to determine optimal conditions for order the drug-resistant distinguishing and between It is quite possible that the drug-sensitive cells. window of time to observe differences for different drugs could vary and require different incubation times for each drug.

The choice of the promoter for expressing luciferase may provide a needed parameter to more readily assess drug action. For example, in the case of <u>E. coli</u>, gyrase promoters are greatly stimulated in the presence of gyrase inhibitors.

Clinical isolates of <u>M. tuberculosis</u> may be transformed with PYUB180 and tested for luciferase activity in the presence and absence of drugs. The luciferase assays with mycobacteriophage infections with lux mycobacteriophages on in <u>vitro-grown M. tuberculosis</u> cells will first be optimized, and then extended to <u>M. tuberculosis</u> cells grown in macrophages or isolated from sputum samples.

Critical Assessment of Drug-Susceptibility Testing

10

As for the detection of M. tuberculosis from clinical samples, the luciferase assay may be optimized so that the drug-susceptibility patterns for any clinical isolate may be obtained. It may be possible to add diagnostic mycobacteriophages to a single clinical specimen, aliquot the mixture into various tubes and add antibiotic drugs. Thus every experiment would have an internal control and each drug-treated sample could be compared to an untreated control. The critical parameter to conclude drug-resistance or sensitivity lies in the comparison.

Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of various aspects of the invention.

Thus, it is to be understood that numerous modifications may be made in the illustrative embodiments and other arrangements may be devised without departing from the spirit and scope of the invention.

20

#### WHAT IS CLAIMED IS:

- mycobacterial producing 1. Α method of mycobacteriophages which species-specific reporter genes and reporter introducing comprises genomes of promoters into the transcriptional mycobacteriophages species-specific mycobacterial wherein upon incubation with the mycobacteria for which said reporter mycobacteriophage is specific, the reporter genes of said reporter mycobacteriophage will express a gene product which is detectable.
- 2. The method according to Claim 1 wherein the reporter genes and transcriptional promoters are introduced into the mycobacteriophages by shuttle phasmid technology.
- 3. The method according to Claim 1 wherein
  15 the reporter genes and transcriptional promoters are
  introduced into the mycobacteriophages by homologous
  recominbation or PCR.
  - 4. The method according to Claim 1 wherein the reporter genes and transcriptional promoters are introduced into the mycobacteriophages by transposon technology.
    - 5. The method according to Claim 1 wherein the r porter genes and transcriptional promoters are

introduced into the mycobacteriophages by debilitated phages packaged into page heads and tails.

- 6. The method according to Claim 1 wherein the reporter genes and transcriptional promoters are introduced into the mycobacteriophages by plasmids packaged into phage heads and tails.
- 7. The method according to Claim 1 wherein the reporter genes and transcriptional promoters are introduced into the mycobacteriophages by recombinant DNA techniques.
- 8. The method according to Claim 1 wherein the mycobacteria is M. tuberculosis.
- 9. The method according to Claim 1 wherein the mycobacterial species-specific mycobacteriophage is L5, TM4 or DS6A.
  - 10. The method according to Claim 1 wherein the reporter genes are luciferase genes or the  $\beta$ -galactosidase gene.
- 11. The method according to Claim 10 wherein the luciferase genes are selected from the group consisting of Firefly <u>lux</u> gene, <u>Vibrio fischeri lux</u> genes, <u>Xenorhabdus luminescens lux</u> genes and <u>lac</u>Z genes.
- 12. The method according to Claim 1 wherein 25 the transcriptional promoter is hsp60 or the L5 gene 62 promoter.

(<sub>3</sub>,...,

C<sub>y</sub>w

- 13. The method according to Claim 1 wherein the gene product is photons.
- 14. The method according to Claim 1 wherein the gene product is made detectable by contacting said gene product with a substrate.
- 15. The method according to Claim 14 wherein the substrate is luciferin or decanal.
- 16. The mycobacterial species-specific reporter mycobacteriophage produced by the method of 10 Claim 1.
- mycobacteriophage comprising a mycobacterial species-specific mycobacteriophage which contains in its genome reporter genes and a transcriptional promoter, wherein the reporter genes express a gene product upon incubation with the mycobacteria for which the reporter mycobacteriophage is specific.
  - 18. The mycobacterial species-specific reporter mycobacteriophage according to Claim 17 wherein the mycobacteria is M. tuberculosis.
  - 19. The mycobacterial species-specific reporter mycobacteriophage according to Claim 17 wherein the mycobacterial species-specific mycobacteriophage is L5, TM4 or DS6A.
- 25 20. The mycobacterial species-specific r porter mycobacteriophage according to Claim 17

wherein the reporter genes are luciferase genes or the ß-galactosidase gene.

- 21. The mycobacterial species-specific reporter mycobacteriophage according to Claim 20 wherein the luciferase genes are selected from the group consisting of Firefly lux gene, Vibrio fischeri lux genes, Xenorhabdus luminescens lux genes and lacz genes.
- 22. The mycobacterial species-specific reporter mycobacteriophage according to Claim 17 wherein the transcriptional promoter is hsp60 or the L5 gene 62 promoter.
- 23. The mycobacterial species-specific reporter mycobacteriophage according to Claim 17

  15 wherein the gene product is photons.
  - 24. The mycobacterial species-specific reporter mycobacteriophage according to Claim 17 wherein the gene product is made detectable by contacting said gene product with a substrate.
  - 25. The mycobacterial species-specific reporter mycobacteriophage according to Claim 24 wherein the substrate is luciferin or decanal.
  - 26. A method of diagnosing a mycobacterial disease which comprises incubating a sample which may contain myco- bacteria with mycobacterial species-specific mycobacteriophages which contain

20

20

reporter genes and transcriptional promoters in their genomes, wherein the reporter genes produce a gene product upon incubation with the mycobacteria for which the mycobacteriophage is specific, and wherein the gene product is detectable.

- 27. The method according to Claim 26 wherein the mycobacterial disease is tuberculosis.
- 28. The method according to Claim 26 wherein the mycobacteria is <u>M. tuberculosis</u>.
- 29. The method according to Claim 26 wherein the mycobacterial species-specific mycobacteriophage is L5, TM4 or DS6A.
- 30. The method according to Claim 26 wherein the reporter genes are luciferase genes or the 15 ß-galactosidase gene.
  - 31. The method according to Claim 30 wherein the luciferase genes are selected from the group consisting of Firefly <u>lux</u> gene, <u>Vibrio fischeri lux</u> genes, <u>Xenorhabdus luminescens lux</u> genes and <u>lac</u>Z genes.
  - 32. The method according to Claim 26 wherein the transcriptional promoter is hsp60 or the L5 gene 62 promoter.
- 33. The method according to Claim 26 wherein25 the gene product is photons.
  - 34. The method according to Claim 26 wherein

(

the gene product is made detectable by contacting said gene product with a substrate.

- 35. The method according to Claim 34 wherein the substrate is luciferin or decanal.
- 36. The method according to Claim 26 wherein the sample is blood or sputum.
  - 37. A method of assessing drug resistance of a mycobacterial strain which comprises:
- (a) incubating a sample which contains a

  myco- bacterial strain with mycobacterial

  species-specific mycobacteriophages which

  contain in their genomes transcriptional

  promoters and reporter genes which

  produce gene products;
  - (b) adding an anti-mycobacterial drug to the incubation; and
    - (c) detecting whether the gene product is present in the sample, such presence indicating drug resistance of the mycobacterial strain.
    - 38. The method according to Claim 37 wherein the mycobacterial strain is a strain of M. tuberculosis.
  - 39. The method according to Claim 37 wherein
    25 the mycobacterial species-specific mycobacteriophage
    is L5, or TM4 or DS6A.

15

20

( ,

20

- 40. The method according to Claim 37 wherein the reporter genes are luciferase genes or the  $\beta$ -galactosidase.
- 41. The method according to Claim 40 wherein the luciferase genes are selected from the group consisting of Firefly <u>lux</u>, gene, <u>Vibrio fischeri lux</u> genes, <u>Xenorhabdus luminescens lux</u> genes and <u>lac</u>Z genes.
- 42. The method according to Claim 37 wherein 10 the gene product is photons.
  - 43. The method according to Claim 37 wherein the transcriptional promoter is hsp60 or the L5 gene 62 promoter.
  - 44. The method according to Claim 37 wherein the anti-mycobacterial drug is selected from the group consisting of streptomycin, isoniazid, ethambutol, rifampicin, ciproflo-xacin, novobiocin and cyanide.
    - 45. The method according to Claim 37 wherein the gene product is made detectable by contacting said gene product with a substrate.
    - 46. The method according to Claim 45 wherein the substrate is luciferin or decanal.
    - 47. The method according to Claim 37 wherein the sample is blood or sputum.

### INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/00913

	SSIFICATION OF SUBJECT MATTER	
	C12N 07/00; C12P 21/06; C12Q 01/66 435/ 235.1, 69.8, 8	
According to	International Patent Classification (IPC) or to both national classification and IPC	·
B. FIEL	DS SEARCHED	
Minimum d	ocumentation searched (classification system followed by classification symbols)	
U.S. : 4	335/ 235.1, 69.8, 8	
	that such decreases and included	in the fields consoled
Documentat	ion searched other than minimum documentation to the extent that such documents are included	ni die lielas scalelled
		·
Electronic d	ata base consulted during the international search (name of data base and, where practicable,	search terms used)
	dialog, aps	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category		( <u>;</u>
Y	US, A, 4,861,709 (Ulitzer et al.) 29 August 1989, see column 8,	1-47
	14-17, and 28.	
Y	Revista Cubana de Medicina Tropical, Volume 41, No. 2, issued	1-47
1	1989, M.C.A. Jimenez et al., "Phage Typing Marker Study of	· · ·
	Mycobacterium-Tuberculosis Strains from Ethiopia Preliminary	
	Report", pages 192-199, see abstract.	
		. 45
<b>Y</b> .	Nature, Volume 351, issued 06 June 1991, C.K. Stover et al., "New	1-47
	Use of BCG for Recombinant Vaccines", pages 456-460, see entire document.	
	document.	•
•		
		• (
•		,
<u> </u>		<u> </u>
	to the second se	
*	ther documents are listed in the continuation of Box C. See patent family annex.	ternational filing date of priority
٠,٠ ه	special estegories of cited documents:  T later document published after the integration of the conflict with the applies	cation but cited to understand the
	ispecial estegories of cited documents:  T is later document published after the interest of the art which is not considered on part of particular relevance:  Is the document defining the general state of the art which is not considered on particular relevance:  To be part of particular relevance:  The document of particular relevance:  The document of particular relevance:  The document of particular relevance:	cation but cited to understand the vention he claimed invention cannot be
*E*	ispecial extegories of cited documents:  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date  To later document published after the interestional filing date	cation but cited to understand the vention he claimed invention cannot be
E.	inter document published after the international filing date  artier document published on or after the international filing date  "X"  document of particular relevance  "X"  document of particular relevance; if  considered novel or cannot be considered  when the document is taken alone  icited to establish the publication date of another citation or other  pecial reason (as specified)	cation but cited to understand the vention  he claimed invention cannot be cred to involve an inventive step  the claimed invention cannot be a step when the document is
.c.	is pecial estegories of cised documents:  The comment defining the general state of the art which is not considered to be part of particular relevance to the part of particular relevance to the considered to th	mation but cited to understand the vention  he claimed invention cannot be ered to involve an inventive step  the claimed invention cannot be a step when the document as ch document, such combination
.b.	is pecial estegories of cised documents:  Incomment defining the general state of the art which is not considered to be part of particular relevance  Incomment which may throw doubts on priority claim(s) or which is side to establish the publication date of another citation or other means  Incomment referring to an oral disclosure, use, exhibition or other means  Incomment published prior to the international filing date but later than the document person skilled in document person skilled in document member of the same pater	cation but cited to understand the vention  the claimed invention cannot be cred to involve an inventive step  the claimed invention cannot be a step when the document is children to act the document in the art
.b. .c. .r.	is pecial estegories of cised documents:  The comment defining the general state of the art which is not considered to be part of particular relevance to be part of particular relevance to the international filing date.  The considered to the conflict with the application of the art which is not considered to the con	ration but cited to understand the vention  he claimed invention cannot be ered to involve an inventive step  the claimed invention cannot be estep when the document as ch document, such combination the art  at family
"E" "C" "P"  Date of th	is pecial estegories of cited documents:  The state of comment of percent state of the art which is not considered to be part of particular relevance; the international filing date  The state and not in conflict with the application of the international filing date  The state and not in conflict with the application or other the international filing date  The state and not in conflict with the application or other the international filing date  The state document of particular relevance; the considered novel or cannot be considered to involve an inventive considered to involve an inventive means  The state document of particular relevance; the considered to involve an inventive considered to involve an inventive means  The state document of particular relevance; the considered to involve an inventive considered to involve an inventive means  The state document of particular relevance; the considered to involve an inventive considered to involve an inventive means  The state document of particular relevance; the considered novel or cannot be considered to involve an inventive considered to involve an inventive means  The state document of particular relevance; the considered to involve an inventive considered to involve an inventive considered to involve an inventive means.	ration but cited to understand the vention  he claimed invention cannot be ered to involve an inventive step  the claimed invention cannot be estep when the document as ch document, such combination the art  at family
"E" "L" "O" "P"  Date of the	is pecial estegories of cised documents:  Indeximent defining the general state of the art which is not considered to be part of particular relevance to be part of particular relevance; the international filing date to establish the publication date of another citation or other means the principle of the international filing date to establish the publication date of another citation or other means (as specified)  The state document published on or after the international filing date to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other means to establish the publication date of another citation or other considered to involve an inventive combined with one or more other surface.  The decument published after the international filing date to establish the another citation or other considered to involve an inventive combined with one or more other surface and the principle or theory underlying the internation of comment and the comment of particular relevance; to considered novel or cannot be considered anovel	ration but cited to understand the vention  he claimed invention cannot be ered to involve an inventive step  the claimed invention cannot be estep when the document as ch document, such combination the art  at family
"E" "O" "P"  Date of the 15 APR  Name and Commiss Box PCT	is pecial estegories of cised documents:  Incomment defining the general state of the art which is not considered to be part of particular relevance to be part of particular relevance; the considered to establish the publication date of another citation or other document referring to an oral disclosure, use, exhibition or other described prior to the international filing date to the priority date claimed  Incomment published prior to the international filing date but later than the priority date claimed  In 1993  In mailing address of the ISA/US and address and Trademarks  In the priority date of ficer to the international search to the i	ration but cited to understand the vention  he claimed invention cannot be ered to involve an inventive step  the claimed invention cannot be estep when the document as ch document, such combination the art  at family
"E" "L" "O" "P"  Date of th  15 APR  Name and Commiss Box PCT Washing	is pecial estegories of cised documents:  Indeximent defining the general state of the art which is not considered to be part of particular relevance the international filing date the international filing date the establish the publication date of another citation or other means the priority date claimed to establish the publication date of another citation or other means the priority date claimed to establish the publication date of another citation or other means the priority date claimed to establish do an oral disclosure, use, exhibition or other means the priority date claimed to international filing date but later than the priority date claimed to international search  IL 1993  I mailing address of the ISA/US tioner of Patents and Trademarks  I attr document published after the international filing date considered to inconflict with the application and the priority date claimed to extend the international search to be considered to involve an inventive combined with one or more others us being obvious to a person skilled in the priority date claimed to international search the international search to the international search t	ration but cited to understand the vention  he claimed invention cannot be ered to involve an inventive step  the claimed invention cannot be estep when the document is ch document is the art  at family

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/00913

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	Folia Microbiology, Volume 36, No. 5, issued 1991, J. Konicek et al., "Gene Manipulation in Mycobacteria", pages 411-422, see pages 415-417.	1-47
Y	Nature, Volume 327, issued 11 June 1987, W.R. Jacobs Jr. et al., "Introduction to Foreign DNA into Mycobacteria using a Shuttle Phasmid", pages 532-535, see entire document.	1-47
Y die	Proceedings of the National Academy of Sciences, Volume 88, issued April 1991, M.H. Lee et al., "Site-specific Integration of Mycobacteriophage L5: Integration-proficient Vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin", pages 3111-3115, see entire document.	1-47
Y	Journal of General Virology, Volume 26, No. 1, issued January 1975, J.A. Hewitt, "Miniphage - a Class of Satellite Phage to M13", pages 87-94, see abstract.	5, 6
Y	Journal of Bacteriology, Volume 149, No. 3, issued March 1982, M.J. Orbach et al., "Transfer of Chimeric Plasmids among Salmonella typhimurium Strains by P22 Transduction", pages 985-994, see entire document.	5, 6
	Zentralbl. Veterinaermed., Reihe B, Volume 25, No. 5, issued	37-47
Y	1982, R. Weiss et al., "Resistance Testing of Bacteria by Firefly Bioluminescence. A Rapid Test", pages 359-71, see abstract.	
•	1982, R. Weiss et al., "Resistance Testing of Bacteria by Firefly Bioluminescence. A Rapid Test", pages 359-71, see abstract.  Fortschr. Veterinaermed., Volume 35, issued 1982, R. Weiss et al., "Bioluminescent Methods to Test the Antibiotic Sensitivity of Bacteria", pages 323-328, see abstract.	37-47
	Bioluminescence. A Rapid Test", pages 359-71, see abstract.  Fortschr. Veterinaermed., Volume 35, issued 1982, R. Weiss et al., "Bioluminescent Methods to Test the Antibiotic Sensitivity of	37-47
•	Bioluminescence. A Rapid Test", pages 359-71, see abstract.  Fortschr. Veterinaermed., Volume 35, issued 1982, R. Weiss et al., "Bioluminescent Methods to Test the Antibiotic Sensitivity of	37-47
	Bioluminescence. A Rapid Test", pages 359-71, see abstract.  Fortschr. Veterinaermed., Volume 35, issued 1982, R. Weiss et al., "Bioluminescent Methods to Test the Antibiotic Sensitivity of	37-47
Y Y	Bioluminescence. A Rapid Test", pages 359-71, see abstract.  Fortschr. Veterinaermed., Volume 35, issued 1982, R. Weiss et al., "Bioluminescent Methods to Test the Antibiotic Sensitivity of	37-47

THIS PAGE BLANK (USPTO)